Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | Apr. 30, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Trading Symbol | FGEN | |
Entity Registrant Name | FIBROGEN, INC. | |
Entity Central Index Key | 0000921299 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Shell Company | false | |
Title of 12(b) Security | Common Stock, $0.01 par value | |
Security Exchange Name | NASDAQ | |
Entity File Number | 001-36740 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 77-0357827 | |
Entity Address, Address Line One | 409 Illinois Street | |
Entity Address, City or Town | San Francisco | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94158 | |
City Area Code | 415 | |
Local Phone Number | 978-1200 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity Common Stock Shares Outstanding | 97,582,416 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 188,550 | $ 155,700 |
Short-term investments | 167,399 | 266,308 |
Accounts receivable, net ($11,563 and $12,088 from related parties) | 17,654 | 16,299 |
Inventories | 42,456 | 40,436 |
Prepaid expenses and other current assets | 14,490 | 14,083 |
Total current assets | 430,549 | 492,826 |
Restricted time deposits | 2,072 | 2,072 |
Long-term investments | 0 | 4,348 |
Property and equipment, net | 18,693 | 20,605 |
Equity method investment in unconsolidated variable interest entity | 5,884 | 5,061 |
Operating lease right-of-use assets | 76,674 | 79,893 |
Other assets | 4,672 | 5,282 |
Total assets | 538,544 | 610,087 |
Current liabilities: | ||
Accounts payable ($57,499 and $0 to a related party) | 71,282 | 30,758 |
Accrued and other current liabilities ($19,594 and $63,886 to a related party) | 157,042 | 219,773 |
Deferred revenue ($13,129 and $9,259 to related parties) | 16,495 | 12,739 |
Operating lease liabilities, current | 9,927 | 10,292 |
Total current liabilities | 254,746 | 273,562 |
Product development obligations | 17,276 | 16,917 |
Deferred revenue, net of current | 163,089 | 185,722 |
Operating lease liabilities, non-current | 76,885 | 79,593 |
Liability related to sale of future revenues, non-current | 48,370 | 49,333 |
Other long-term liabilities ($1,618 and $0 to a related party) | 7,063 | 6,440 |
Total liabilities | 567,429 | 611,567 |
Commitments and Contingencies (Note 10) | ||
Stockholders' deficit: | ||
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at March 31, 2023 and December 31, 2022 | ||
Common stock, $0.01 par value; 225,000 shares authorized at March 31, 2023 and December 31, 2022; 96,623 and 94,166 shares issued and outstanding at March 31, 2023 and December 31, 2022 | 966 | 942 |
Additional paid-in capital | 1,589,145 | 1,541,019 |
Accumulated other comprehensive loss | (4,570) | (5,720) |
Accumulated deficit | (1,634,393) | (1,557,688) |
Total stockholders' deficit | (48,852) | (21,447) |
Non-controlling interests | 19,967 | 19,967 |
Total deficit | (28,885) | (1,480) |
Total liabilities, stockholders' deficit and non-controlling interests | $ 538,544 | $ 610,087 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Accounts receivable from related parties | $ 11,563 | $ 12,088 |
Accounts payable to related party | 57,499 | 0 |
Accrued and other current liabilities to related party | 19,594 | 63,886 |
Deferred revenue current to related party | 13,129 | 9,259 |
Deferred revenue non-current to related party | 10,245 | 31,044 |
Other long-term liabilities due to related party | $ 1,618 | $ 0 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 125,000,000 | 125,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 225,000,000 | 225,000,000 |
Common stock, shares issued | 96,623,000 | 94,166,000 |
Common stock, shares outstanding | 96,623,000 | 94,166,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue: | ||
Total revenue | $ 36,161 | $ 60,827 |
Operating costs and expenses: | ||
Cost of goods sold | $ 3,491 | $ 4,238 |
Cost, Product and Service [Extensible List] | Product Revenue, Net [Member] | Product Revenue, Net [Member] |
Research and development | $ 74,486 | $ 89,018 |
Selling, general and administrative | 34,275 | 30,564 |
Total operating costs and expenses | 112,252 | 123,820 |
Loss from operations | (76,091) | (62,993) |
Interest and other, net | ||
Interest expense | (2,372) | (97) |
Interest income and other income (expenses), net | 1,036 | (322) |
Total interest and other, net | (1,336) | (419) |
Loss before income taxes | (77,427) | (63,412) |
Provision for income taxes | 74 | 113 |
Investment income in unconsolidated variable interest entity | 796 | 320 |
Net loss | $ (76,705) | $ (63,205) |
Net income (loss) per share - basic | $ (0.81) | $ (0.68) |
Net income (loss) per share - diluted | $ (0.81) | $ (0.68) |
Weighted average number of common shares used to calculate net income (loss) per share: | ||
Basic | 94,691 | 93,043 |
Diluted | 94,691 | 93,043 |
License Revenue [Member] | ||
Revenue: | ||
Total revenue | $ 6,000 | $ 22,590 |
Development and Other Revenue [Member] | ||
Revenue: | ||
Total revenue | 3,891 | 11,762 |
Product Revenue, Net [Member] | ||
Revenue: | ||
Total revenue | 24,161 | 18,881 |
Drug Product Revenue [Member] | ||
Revenue: | ||
Total revenue | $ 2,109 | $ 7,594 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - Astellas Agreement [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
License and milestone revenue from a related party | $ 0 | $ 22,590 |
Collaboration services and other revenue from a related party | 1,624 | 5,180 |
Product revenue from a related party | 21,372 | 16,223 |
Drug product revenue from a related party | $ 2,109 | $ 7,594 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Statement of Comprehensive Income [Abstract] | ||
Net loss | $ (76,705) | $ (63,205) |
Other comprehensive income (loss): | ||
Foreign currency translation adjustments | (248) | 249 |
Available-for-sale investments: | ||
Unrealized gain (loss) on investments, net of tax effect | 1,398 | (2,591) |
Other comprehensive gain (loss), net of taxes | 1,150 | (2,342) |
Comprehensive loss | $ (75,555) | $ (65,547) |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Accumulated Deficit [Member] | Noncontrolling Interests [Member] |
Balance at Dec. 31, 2021 | $ 229,113 | $ 929 | $ 1,476,414 | $ (4,163) | $ (1,264,034) | $ 19,967 |
Balance, Shares at Dec. 31, 2021 | 92,880,533 | |||||
Net loss | (63,205) | $ 0 | 0 | 0 | (63,205) | 0 |
Change in unrealized gain or loss on investments | (2,591) | 0 | 0 | (2,591) | 0 | 0 |
Foreign currency translation adjustments | 249 | 0 | 0 | 249 | 0 | 0 |
Shares issued from stock plans, net of payroll taxes paid | (2,703) | $ 4 | (2,707) | 0 | 0 | 0 |
Shares issued from stock plans, net of payroll taxes paid, Shares | 408,051 | |||||
Stock-based compensation | 17,152 | $ 0 | 17,152 | 0 | 0 | 0 |
Balance at Mar. 31, 2022 | 178,015 | $ 933 | 1,490,859 | (6,505) | (1,327,239) | 19,967 |
Balance, Shares at Mar. 31, 2022 | 93,288,584 | |||||
Balance at Dec. 31, 2022 | (1,480) | $ 942 | 1,541,019 | (5,720) | (1,557,688) | 19,967 |
Balance, Shares at Dec. 31, 2022 | 94,166,086 | |||||
Net loss | (76,705) | $ 0 | 0 | 0 | (76,705) | 0 |
Change in unrealized gain or loss on investments | 1,398 | 0 | 0 | 1,398 | 0 | 0 |
Foreign currency translation adjustments | (248) | 0 | 0 | (248) | 0 | 0 |
Issuance of common stock under ATM Program | 31,131 | $ 15 | 31,116 | 0 | 0 | 0 |
Issuance of common stock under ATM Program shares | 1,541,579 | |||||
Shares issued from stock plans, net of payroll taxes paid | 907 | $ 9 | 898 | 0 | 0 | 0 |
Shares issued from stock plans, net of payroll taxes paid, Shares | 915,644 | |||||
Stock-based compensation | 16,112 | $ 0 | 16,112 | 0 | 0 | 0 |
Balance at Mar. 31, 2023 | $ (28,885) | $ 966 | $ 1,589,145 | $ (4,570) | $ (1,634,393) | $ 19,967 |
Balance, Shares at Mar. 31, 2023 | 96,623,309 |
Condensed Consolidated Statem_5
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Operating activities | ||
Net loss | $ (76,705) | $ (63,205) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation | 2,542 | 2,450 |
Amortization of finance lease right-of-use assets | 423 | 134 |
Net accretion of premium and discount on investments | (689) | 928 |
Investment income in unconsolidated variable interest entity | (796) | (320) |
Loss on disposal of property and equipment | 1 | 5 |
Stock-based compensation | 16,112 | 17,152 |
Non-cash interest expense related to sale of future revenues | 2,249 | 0 |
Impairment of investment | 1,000 | 0 |
Realized loss on sales of available-for-sale securities | 271 | 5 |
Changes in operating assets and liabilities: | ||
Accounts receivable, net | (1,299) | (26,481) |
Inventories | (1,940) | (12,000) |
Prepaid expenses and other current assets | 38 | 11,382 |
Operating lease right-of-use assets | 3,237 | 3,132 |
Other assets | 1,072 | (459) |
Accounts payable | 40,473 | 10,207 |
Accrued and other liabilities | (66,266) | 65,993 |
Operating lease liabilities, current | (371) | 31 |
Deferred revenue | (18,877) | (13,024) |
Accrued interest for finance lease liabilities | (56) | (21) |
Operating lease liabilities, non-current | (2,720) | (2,835) |
Other long-term liabilities | 710 | (1,550) |
Net cash used in operating activities | (101,591) | (8,476) |
Investing activities | ||
Purchases of property and equipment | (591) | (1,638) |
Payment made for acquired in-process research and development asset | 0 | (35,000) |
Purchases of available-for-sale securities | (2,472) | (20,912) |
Proceeds from sales of available-for-sale securities | 1,730 | 7,382 |
Proceeds from maturities of investments | 104,815 | 76,103 |
Net cash provided by investing activities | 103,482 | 25,935 |
Financing activities | ||
Repayments of finance lease liabilities | (71) | (1) |
Repayments of lease obligations | (101) | (101) |
Cash paid for payroll taxes on restricted stock unit releases | 0 | (2,974) |
Proceeds from issuance of common stock under ATM Program, net of commissions | 30,750 | 0 |
Proceeds from issuance of common stock under employee stock plans | 907 | 183 |
Net cash provided by (used in) financing activities | 31,485 | (2,893) |
Effect of exchange rate change on cash and cash equivalents | (526) | 107 |
Net increase in cash and cash equivalents | 32,850 | 14,673 |
Total cash and cash equivalents at beginning of period | 155,700 | 171,223 |
Total cash and cash equivalents at end of period | $ 188,550 | $ 185,896 |
Significant Accounting Policies
Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies | 1. Significant Accounting Policies Description of Operations FibroGen, Inc. (“FibroGen” or the “Company”) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”). FibroGen is a leading biopharmaceutical company discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (“HIF”) biology, 2-oxoglutarate enzymology, and connective tissue growth factor to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy. To date, the Company has retained exclusive worldwide rights for pamrevlumab. Roxadustat is an oral small molecule inhibitor of HIF prolyl hydroxylase activity. Roxadustat (爱瑞卓 ® , EVRENZO TM ) is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease for patients who are on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development for anemia associated with myelodysplastic syndromes, in the United States (“U.S.”) and Europe, and chemotherapy-induced anemia in China. The Company has a pipeline of late-stage clinical programs as well as preclinical drug candidates at various stages of development that include both small molecules and biologics. FibroGen’s goal is to build a diversified pipeline with novel drugs that will address unmet patient needs in oncology, immunology, and fibrosis. Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements include the accounts of FibroGen, its wholly-owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity (“VIE”) for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one reportable segment — the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 , filed on February 27, 2023 (“2022 Form 10-K”). Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented. Significant Accounting Policies The accounting policies used by the Company in its presentation of interim financial results are consistent with those presented in Note 2 to the consolidated financial statements included in the 2022 Form 10-K. Net Loss per Share Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. The Company reported a net loss for the three months ended March 31, 2023 and 2022. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive for these periods. Diluted weighted average shares excluded the following potential common shares related to s tock options, service-based restricted stock units (“RSUs”), performance-based RSUs (“PRSUs”), total shareholder return (“TSR”) awards and shares to be purchased under the 2014 Employee Stock Purchase Plan (“ESPP”) for the periods presented as they were anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Employee stock options 7,578 9,484 RSUs, PRSUs and TSR awards 2,762 2,196 ESPP 362 473 10,702 12,153 Risks and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the results of clinical trials and the achievement of milestones, research developments, actions by regulatory authorities, market acceptance of the Company’s product candidates, competition from other products and larger companies, the liquidity and capital resources of the Company, intellectual property protection for the Company’s proprietary technology, strategic relationships, and dependence on key individuals, suppliers, clinical organization, and other third parties. |
Collaboration Agreements, Licen
Collaboration Agreements, License Agreement and Revenues | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaboration Agreements, License Agreement and Revenues | 2. Collaboration Agreements, License Agreement and Revenues Astellas Agreements Astellas Japan Agreement In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Astellas Japan Agreement”). Under this agreement, Astellas agreed to pay license fees, other upfront consideration and various milestone payments, totaling $ 172.6 million . The Astellas Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan’s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through March 31, 2023 totaled $ 105.1 million , excluding drug product revenue that is discussed under the Drug Product Revenue section below. Amounts recognized as license revenue and development revenue under the Astellas Japan Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Astellas Japan Agreement License revenue $ — $ — Development revenue $ 95 $ 32 The transaction price related to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the Astellas Japan Agreement (in thousands): Astellas Japan Agreement Total Consideration License $ 100,347 Development revenue 16,977 Total license and development revenue $ 117,324 There was no license revenue or development revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods for the three months ended March 31, 2023 under the Astellas Japan Agreement. The Company does no t expect material variable consideration from estimated future co-development billing beyond the development period in the transaction price related to the Astellas Japan Agreement. In 2018, FibroGen and Astellas entered into an amendment to the Astellas Japan Agreement that allows Astellas to manufacture roxadustat drug product for commercialization in Japan (the “Astellas Japan Amendment”). The related drug product revenue is described under the Drug Product Revenue section below. Astellas Europe Agreement In April 2006, the Company entered into a separate collaboration agreement with Astellas for the development and commercialization of roxadustat for the treatment of anemia in Europe, the Middle East, the Commonwealth of Independent States and South Africa (“Astellas Europe Agreement”). Under the terms of the Astellas Europe Agreement, Astellas agreed to pay license fees, other upfront consideration and various milestone payments, totaling $ 745.0 million . U nder the Astellas Europe Agreement, Astellas committed to fund 50 % of joint development costs for Europe and North America, and all territory-specific costs. The Astellas Europe Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range . On March 21, 2022, EVRENZO ® (roxadustat) was registered with the Russian Ministry of Health. The Company evaluated the regulatory milestone payment associated with the approval in Russia under the Astellas Europe Agreement and concluded that this milestone was achieved in the first quarter of 2022. Accordingly, the consideration of $ 25.0 million associated with this milestone was included in the transaction price and allocated to performance obligations under the Astellas Europe Agreement, all of which was recognized as revenue during the first quarter of 2022 from performance obligations satisfied. The aggregate amount of consideration received under the Astellas Europe Agreement through March 31, 2023 totaled $ 685.0 million , excluding drug product revenue that is discussed under the Drug Product Revenue section below. Amounts recognized as license revenue and development revenue under the Astellas Europe Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Astellas Europe Agreement License revenue $ — $ 22,590 Development revenue $ 1,529 $ 5,148 The transaction price related to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the Astellas Europe Agreement as follows (in thousands): Astellas Europe Agreement Total Consideration License $ 618,975 Development revenue 281,794 Total license and development revenue $ 900,769 There was no license revenue or development revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods for three months ended March 31, 2023 under the Astellas Europe Agreement. The remainder of the transaction price related to the Astellas Europe Agreement includes $ 5.8 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period. Under the Astellas Europe Agreement, Astellas has an option to purchase roxadustat bulk drug product in support of commercial supplies. During the first quarter of 2021, the Company entered into an EU Supply Agreement with Astellas under the Astellas Europe Agreement (“Astellas EU Supply Agreement”) to define general forecast, order, supply and payment terms for Astellas to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The related drug product revenue is described under the Drug Product Revenue section below. AstraZeneca Agreements AstraZeneca U.S./Rest of World (“RoW”) Agreement Effective July 30, 2013, the Company entered into a collaboration agreement with AstraZeneca AB (“AstraZeneca”) for the development and commercialization of roxadustat for the treatment of anemia in the U.S. and all other countries in the world, other than China, not previously licensed under the Astellas Europe and Astellas Japan Agreements (“AstraZeneca U.S./RoW Agreement”). It also excludes China, which is covered by a separate agreement with AstraZeneca described below. Under the terms of the AstraZeneca U.S./RoW Agreement, AstraZeneca agreed to pay upfront, non-contingent, non-refundable and time-based payments, and potential milestone payments, totaling $ 1.2 billion . AstraZeneca commits to pay the Comp any tiered royalty payments on AstraZeneca’s future net sales (as defined in the agreement) of roxadustat in the low 20% range . In addition, the Company is entitled to receive a transfer price for shipment of commercial product based on a percentage of AstraZeneca’s net sales (as defined in the agreement) in the low- to mid-single digit range. The aggregate amount of consideration received under the AstraZeneca U.S./RoW Agreement through March 31, 2023 totaled $ 439.0 million , excluding drug product revenue that is discussed separately below. While FibroGen and AstraZeneca continue to develop roxadustat in the U.S. for the treatment of anemia in patients with myelodysplastic syndromes, the Company has not been able to agree on a path forward for AstraZeneca to fund further roxadustat development for chronic kidney disease anemia in the U.S. Therefore, the Company does not expect to receive most or all of the remaining AstraZeneca U.S./RoW Agreement milestones from AstraZeneca. In 2020, the Company entered into a Master Supply Agreement with AstraZeneca under the AstraZeneca U.S./RoW Agreement (“AstraZeneca Master Supply Agreement”) to define general forecast, order, supply and payment terms for AstraZeneca to purchase roxadustat bulk drug product from FibroGen in support of commercial supplies. The related drug product revenue is described under the Drug Product Revenue section below. AstraZeneca China Agreement Effective July 30, 2013, the Company (through its subsidiaries affiliated with China) entered into a collaboration agreement with AztraZeneca for roxadustat for the treatment of anemia in China (“AstraZeneca China Agreement”). Under the terms of the AstraZeneca China Agreement, AstraZeneca agreed to pay upfront consideration and potential milestone payments, totaling $ 376.7 million . The AstraZeneca China Agreement is structured as a 50/50 profit or loss share (as defined), which was amended under the AstraZeneca China Amendment in 2020 as discussed below, and provides for joint development costs (including capital and equipment costs for construction of the manufacturing plant in China), to be shared equally during the development period. The aggregate amount of such consideration received for milestone and upfront payments through March 31, 2023 totaled $ 77.2 million . AstraZeneca China Amendment In July 2020, FibroGen China Anemia Holdings, Ltd., FibroGen (China) Medical Technology Development Co., Ltd. (“FibroGen Beijing”), and FibroGen International (Hong Kong) Limited and AstraZeneca entered into an amendment to the AstraZeneca China Amendment, relating to the development and commercialization of roxadustat in China (the “AstraZeneca China Amendment”). Under the AstraZeneca China Amendment, in 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Beijing Falikang Pharmaceutical Co., Ltd. (“Falikang”), which performs roxadustat distribution, as well as conducts sales and marketing through AstraZeneca. Substantially all direct roxadustat product sales to distributors in China are made by Falikang, while FibroGen Beijing continues to sell roxadustat product directly in one province in China. FibroGen Beijing manufactures and supplies commercial product to Falikang based on a gross transfer price, which is adjusted for the estimated profit share. Amounts recognized as license revenue and development revenue under the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement License revenue $ — $ — Development revenue 2,032 5,819 The transaction price relat ed to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement, along with any associated deferred revenue as follows (in thousands): AstraZeneca U.S./RoW Agreement and Cumulative Revenue Deferred Revenue at Total Consideration License $ 341,844 $ — $ 341,844 Co-development, information sharing & 617,670 — 617,670 China performance obligation * 128,106 175,326 303,432 Total license and development revenue $ 1,087,620 $ 175,326 ** $ 1,262,946 * China performance obligation revenue is recognized as product revenue, as described under Product Revenue, Net section below. ** Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of March 31, 2023, deferred revenue included $ 156.2 million related to the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement, which represents the net of $ 175.3 million of deferred revenue presented above and a $ 19.1 million unbilled co-development revenue under the AstraZeneca China Amendment. There was no license revenue or development revenue resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied or partially satisfied in previous periods for the three months ended March 31, 2023 under the AstraZeneca U.S./RoW Agreement. The remainder of the transaction price related to the AstraZeneca U.S./R oW Agreement and AstraZeneca China Agreement includes $ 9.8 million of variable consideration from estimated future co-development billing and is expected to be recognized over the remaining development service period, except for amounts allocated to the China performance obligation. The amount allocated to the China performance obligation is expected to be recognized as the Company transfers control of the commercial drug product to Falikang, and is expected to continue through 2028, which reflects our best estimates. The net product revenue from the sales to Falikang and the net product revenue from direct sales distributors in China are described under Product Revenue, Net section below. Product Revenue, Net Product revenue, net from the sales of roxadustat commercial product in China was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Direct Sales: Gross revenue $ 3,060 $ 2,830 Discounts and rebates ( 273 ) ( 175 ) Sales returns 2 3 Direct sales revenue, net 2,789 2,658 Sales to Falikang: Gross transaction price 34,249 22,726 Profit share ( 14,988 ) ( 8,849 ) Net transaction price 19,261 13,877 Decrease in deferred revenue 2,111 2,346 Sales to Falikang revenue, net 21,372 16,223 Total product revenue, net $ 24,161 $ 18,881 Direct Sales Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were immaterial for the periods presented. Due to the Company’s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company’s legal right to offset is calculated at the individual distributor level. The contract liabilities were included in accrued and other current liabilities in the condensed consolidated balance sheet and were immaterial as of March 31, 2023 and December 31, 2022, respectively. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales were immaterial as of March 31, 2023 and December 31, 2022, respectively. Sales to Falikang – China Performance Obligation Substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing’s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period. The roxadustat sales to Falikang marked the beginning of the Company’s China performance obligation under the Company’s agreements with AstraZeneca . Product revenue is based on the transaction price of the China performance obligation. Revenue is recognized when control of the product is transferred to Falikang, in an amount that reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period. Any net transaction price in excess of the revenue recognized is added to the deferred balance to date, and will be recognized in future periods as the performance obligation is satisfied. Periodically, the Company updates its assumptions such as total sales quantity, performance period and other inputs including foreign currency translation impact, among others. Following updates to its estimates, the Company recognized $ 2.1 million and $ 2.3 million from the previously deferred revenue of the China performance obligation during the three months ended March 31, 2023 and 2022, respectively. The product revenue recognized for the three months ended March 31, 2023 included a decrease in revenue of $ 0.3 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied in previous periods. The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands): Balance at Additions Recognized as Revenue Currency Balance at Product revenue - AstraZeneca China $ ( 175,646 ) $ ( 20,889 ) $ 21,372 $ ( 163 ) $ ( 175,326 ) Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of March 31, 2023 , approximately $ 22.5 million of the above deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China. Due to the Company’s legal right to offset, at each balance sheet date, the rebates and discounts, mainly related to profit sharing, are presented as reductions to gross accounts receivable from Falikang, which was $ 2.2 million and $ 0.5 million as of March 31, 2023 and December 31, 2022 , respectively. Drug Product Revenue Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Astellas Japan Agreement $ 1,732 $ 7,594 Astellas Europe Agreement 377 — Drug product revenue $ 2,109 $ 7,594 Astellas Japan Agreement During the three months ended March 31, 2023, the Company updated its estimate of variable consideration related to the API shipments fulfilled under the terms of Astellas Japan Amendment, and accordingly recorded adjustments to the drug product revenue of $ 1.7 million. Specifically, the change in estimated variable consideration was based on the API held by Astellas at period end, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, and estimated yield from the manufacture of bulk product tablets, among others. During the three months ended March 31, 2022, the Company fulfilled a shipment obligation under the terms of Astellas Japan Amendment, and recognized related drug product revenue of $ 9.8 million in the same period. In addition, the Company updated its estimate of variable consideration related to the API shipments fulfilled under the terms of Astellas Japan Amendment, and recorded a reduction to the drug product revenue of $ 2.2 million during the first quarter of 2022. Specifically, the change in estimated variable consideration was based on the API held by Astellas at period end, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. As of March 31, 2023, t he balances related to the API price true-up under the Astellas Japan Agreement were $ 3.2 million in accrued liabilities and $ 1.6 million in other long-term liabilities, representing the Company’s best estimate of the timing for these amounts to be paid. As of December 31, 2022, the related balance in accrued liabilities was $ 6.5 million. Astellas Europe Agreement The Company transferred bulk drug product for commercial purposes under the terms of the Astellas Europe Agreement and the Astellas EU Supply Agreement in the prior years, and recognized the related fully burdened manufacturing costs as drug product revenue in the respective periods and recorded the constrained transaction price in deferred revenue due to a high degree of uncertainty associated with the variable consideration for revenue recognition purposes. During the first quarter of 2022, the Company updated its estimate of variable consideration related to the bulk drug product transferred in prior years. Specifically, the change in estimated variable consideration was based on the bulk drug product held by Astellas at the period end, adjusted to reflect the changes in the estimated transfer price, forecast information, shelf-life estimates and other items. As a result, the Company reclassified the related deferred revenue to accrued liabilities during the year ended December 31, 2022. As of December 31, 2022, the related balance was $ 57.4 million in accrued liabilities. Further during the three months ended March 31, 2023 , the Company reclassified $ 16.6 million from the related deferred revenue to accrued liabilities. As of March 31, 2023, the balances related to the bulk drug product price true-up under the Astellas Europe Agreement and the Astellas EU Supply Agreement were $ 57.5 million in accounts payable and $ 16.4 million in a ccrued liabilities, representing the Company’s best estimate that these amounts will be paid within the next 12 months. The Company recognized royalty revenue of $ 0.4 million as drug product revenue from the deferred revenue under the Astellas Europe Agreement during the three months ended March 31, 2023. It is the Company’s best estimate that the remainder of the deferred revenue will be recognized as revenue when uncertainty is resolved, based on the performance of roxadustat product sales in the Astellas territory. The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands): Balance at Additions Recognized as Revenue Reclassified to Accrued Liability / Accounts Payable Balance at Drug product revenue - deferred revenue: Astellas Europe Agreement $ ( 40,303 ) $ — $ 377 $ 16,552 $ ( 23,374 ) AstraZeneca U.S./RoW Agreement There was no shipment of bulk drug product to AstraZeneca as commercial supply under the terms of the AstraZeneca Master Supply Agreement during the three months ended March 31, 2023 and 2022. During the first quarter of 2022, the Company evaluated the current developments in the U.S. market, and updated its estimates of variable consideration associated with bulk drug product shipments to AstraZeneca in prior years as commercial supply. As a result, the Company reclassified $ 11.2 million from the related deferred revenue to accrued liabilities during the year ended December 31, 2022. As of each of March 31, 2023 and December 31, 2022, the related balance in accrued liabilities was $ 11.2 million, representing the Company’s best estimate that this amount will be paid within the next 12 months . Eluminex Agreement In July 2021, FibroGen exclusively licensed to Eluminex Biosciences (Suzhou) Limited (“Eluminex”) global rights to its investigational biosynthetic cornea derived from recombinant human collagen Type III. Under the terms of the agreement with Eluminex , as amended and restated, Eluminex made an $ 8.0 million upfront payment to FibroGen during the first quarter of 2022, which was recognized as license revenue for the performance obligation satisfied during 2021 . In addition, FibroGen may receive up to a total of $ 64.0 million in future manufacturing, clinical, regulatory, and commercial milestone payments for the biosynthetic cornea program, as well as $ 36.0 million in commercial milestones for the first recombinant collagen III product that is not the biosynthetic cornea. FibroGen will also be eligible to receive mid-single-digit to low double-digit royalties based upon worldwide net sales of cornea products, and low single-digit to mid-single-digit royalties based upon worldwide n et sales of other recombinant human collagen type III products that are not cornea products. During the three months ended March 31, 2023 , the Company recognized a $ 3.0 million milestone payment based on Eluminex implanting a biosynthetic cornea in the first patient of its clinical trial in China, and a $ 3.0 million manufacturing related milestone payment. During the first quarter of 2022, FibroGen and Eluminex entered into a separate contract manufacturing agreement, under which the Company is responsible for supplying the cornea product at cost plus 10 % of its product manufacturing costs until its manufacturing technology is fully transferred to Eluminex . The related contract manufacturing revenue was recorded as other revenue and included in development and other revenue in the condensed consolidated statement of operations. Amounts recognized as revenue under the Eluminex were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Eluminex License revenue $ 6,000 $ — Other revenue - contract manufacturing $ 235 $ 762 |
Equity method investment - Vari
Equity method investment - Variable Interest Entity | 3 Months Ended |
Mar. 31, 2023 | |
Acquisition And Variable Interest Entity [Abstract] | |
Equity method investment - Variable Interest Entity | 3. Equity method investment - Variable Interest Entity Falikang is a distribution entity jointly owned by AstraZeneca and FibroGen Beijing. FibroGen Beijing owns 51.1 % of the outstanding shares of Falikang. Pursuant to the guidance under ASC 810, Consolidation (“ASC 810”), the Company concluded that Falikang qualifies as a VIE. As Falikang is a distribution entity and AstraZeneca is the final decision maker for all the roxadustat commercialization activities, the Company lacks the power criterion, while AstraZeneca meets both the power and economic criteria under the ASC 810 to direct the activities of Falikang that most significantly impact its performance. Therefore, the Company is not the primary beneficiary of this VIE for accounting purposes. As a result, the Company accounts for its investment in Falikang under the equity method, and Falikang is not consolidated into the Company’s condensed consolidated financial statements. The Company records its total investments in Falikang as an equity method investment in an unconsolidated VIE in the condensed consolidated balance sheet. In addition, the Company recognizes its proportionate share of the reported profits or losses of Falikang as investment gain or loss in unconsolidated VIE in the condensed consolidated statement of operations and as an adjustment to its investment in Falikang in the condensed consolidated balance sheet. Falikang has not incurred material profit or loss to date. The Company may provide shareholder loans to Falikang to meet necessary financial obligations as part of its operations. To date, there has been no such loans. The Company’s equity method investment in Falikang was as follows (in thousands): Entity Ownership Percentage Balance at Share of Net Income Currency Balance at Falikang 51.1 % $ 5,061 $ 796 $ 27 $ 5,884 Falikang is considered a related party to the Company. See Note 9, Related Party Transactions , for related disclosures. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | 4. Fair Value Measurements The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 42,740 $ — $ — $ 42,740 Corporate bonds — 41,304 — 41,304 Commercial paper — 42,970 — 42,970 U.S. government bonds 57,141 14,425 — 71,566 Agency bonds — 9,075 — 9,075 Asset-backed securities — 2,484 — 2,484 Total $ 99,881 $ 110,258 $ — $ 210,139 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 19,881 $ — $ — $ 19,881 Corporate bonds — 82,008 — 82,008 Commercial paper — 57,381 — 57,381 U.S. government bonds 98,972 12,373 — 111,345 Agency bonds — 11,468 — 11,468 Asset-backed securities — 2,474 — 2,474 Foreign government bonds — 4,980 — 4,980 Convertible promissory note — — 1,000 1,000 Total $ 118,853 $ 170,684 $ 1,000 $ 290,537 The Company’s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data, and other observable inputs. During the three months ended March 31, 2023 , a total of $ 7.0 million of US treasury notes and bills were transferred from Level 1 to Level 2 as such instruments were changed to off-the-run when they were issued before the most recent issue and were still outstanding at measurement day. |
Balance Sheet Components
Balance Sheet Components | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Balance Sheet Components | 5. Balance Sheet Components Cash and Cash Equivalents Cash and cash equivalents consisted of the following (in thousands): March 31, 2023 December 31, 2022 Cash $ 145,810 $ 135,819 Money market funds 42,740 19,881 Total cash and cash equivalents $ 188,550 $ 155,700 At March 31, 2023 and December 31, 2022, a total of $ 98.9 million and $ 92.5 million of the Company’s cash and cash equivalents were held outside of the U.S. in its foreign subsidiaries to be used primarily for its China operations, respectively. Investments The Company’s investments consist primarily of available-for-sale debt investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands): March 31, 2023 Amortized Cost Gross Unrealized Gross Unrealized Estimated Corporate bonds $ 41,760 $ 1 $ ( 457 ) $ 41,304 Commercial paper 42,970 — — 42,970 U.S. government bonds 72,130 1 ( 565 ) 71,566 Agency bonds 9,183 — ( 108 ) 9,075 Asset-backed securities 2,491 — ( 7 ) 2,484 Total investments $ 168,534 $ 2 $ ( 1,137 ) $ 167,399 December 31, 2022 Amortized Cost Gross Unrealized Gross Unrealized Estimated Corporate bonds $ 83,080 $ — $ ( 1,072 ) $ 82,008 Commercial paper 57,381 — — 57,381 U.S. government bonds 112,547 5 ( 1,207 ) 111,345 Agency bonds 11,690 — ( 222 ) 11,468 Asset-backed securities 2,484 — ( 10 ) 2,474 Foreign government bonds 5,007 — ( 27 ) 4,980 Convertible promissory note 1,000 — — 1,000 Total investments $ 273,189 $ 5 $ ( 2,538 ) $ 270,656 The following table summarizes, for all available for sale securities in an unrealized loss position, the fair value and gross unrealized loss by length of time the security has been in a continual unrealized loss position (in thousands): March 31, 2023 Less than 12 Months 12 Months or More Total Estimated Gross Unrealized Estimated Gross Unrealized Estimated Gross Unrealized Corporate bonds $ 2,469 $ ( 7 ) $ 36,084 $ ( 450 ) $ 38,553 $ ( 457 ) U.S. government bonds 4,955 ( 1 ) 43,794 ( 564 ) 48,749 ( 565 ) Agency bonds — — 9,075 ( 108 ) 9,075 ( 108 ) Asset-backed securities 2,483 ( 7 ) — — 2,483 ( 7 ) Total $ 9,907 $ ( 15 ) $ 88,953 $ ( 1,122 ) $ 98,860 $ ( 1,137 ) December 31, 2022 Less than 12 Months 12 Months or More Total Estimated Gross Unrealized Estimated Gross Unrealized Estimated Gross Unrealized Corporate bonds $ 6,738 $ ( 147 ) $ 75,270 $ ( 925 ) $ 82,008 $ ( 1,072 ) U.S. government bonds 22,326 ( 13 ) 67,909 ( 1,194 ) 90,235 ( 1,207 ) Agency bonds — — 11,468 ( 222 ) 11,468 ( 222 ) Asset-backed securities 2,474 ( 10 ) — — 2,474 ( 10 ) Foreign government bonds - — 4,980 ( 27 ) 4,980 ( 27 ) Total $ 31,538 $ ( 170 ) $ 159,627 $ ( 2,368 ) $ 191,165 $ ( 2,538 ) At March 31, 2023, the available-for-sale investments had remaining contractual maturities of less than twelve months. The Company periodically reviews its available-for-sale investments for other-than-temporary impairment. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, the Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. Based on the results of its review, the Company did no t recognize any other-than-temporary impairment loss during the three months ended March 31, 2023 and 2022. Inventories Inventories consisted of the following (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 1,226 $ 1,241 Work-in-progress $ 37,273 36,003 Finished goods $ 3,957 3,192 Total inventories $ 42,456 $ 40,436 Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following (in thousands): March 31, 2023 December 31, 2022 Preclinical and clinical trial accruals $ 42,953 $ 57,780 API and bulk drug product price true-up 30,758 75,055 Payroll and related accruals 12,230 22,562 Accrued co-promotion expenses - current 36,688 36,677 Roxadustat profit share to AstraZeneca 7,311 7,280 Property taxes and other taxes 8,041 7,691 Professional services 8,354 5,480 Current portion of liability related to sale of future revenues 3,212 — Other 7,495 7,248 Total accrued and other current liabilities $ 157,042 $ 219,773 The accrued liabilities of $ 30.8 million for API and bulk drug product price true-up as of March 31, 2023 resulted from changes in estimated variable consideration associated with the API shipments fulfilled under the terms of the Astellas Japan Amendment, the bulk drug product transferred under the terms of the Astellas Europe Agreement and the Astellas EU Supply Agreement, and the bulk drug product shipments to AstraZeneca under the terms of the AstraZeneca Master Supply Agreement. See the Drug Product Revenue section in Note 2, Collaboration Agreements, License Agreement and Revenues, for details. |
Liability Related to Sale of Fu
Liability Related to Sale of Future Revenues | 3 Months Ended |
Mar. 31, 2023 | |
Liability Related to Sale of Future Royalties [Abstract] | |
Liability Related to Sale of Future Revenues | 6. Liability Related to Sale of Future Revenues On November 4, 2022, the Company entered into a Revenue Interest Financing Agreement (the “RIFA”) with an affiliate of NovaQuest Capital Management (“NovaQuest”), pursuant to which the Company granted NovaQuest 22.5 % of its drug product revenue and 10.0 % ( 20.0 % for fiscal year 2028 and thereafter) of its revenue from milestone payments that it is entitled to under the Astellas Agreements , for a consideration of $ 50.0 million (“Investment Amount”) before advisory fees. In November 2022, the Company received the Investment Amount, net of initial issuance costs, and accounted for it as long-term debt based on the terms of the RIFA because the risks and rewards to NovaQuest are limited by the terms of the transaction. The related debt discount and transaction costs are amortized as interest expense based on the projected balance of the liability as of the beginning of each period. As payments are made to NovaQuest, the balance of the liability related to sale of future revenues is being effectively repaid over the life of the RIFA. The payments to NovaQuest are accounted for as a reduction of debt. The Company may prepay its obligations to NovaQuest in full at any time during the term of RIFA. The prepayment amount varies from $ 80.0 million to $ 125.0 million less any revenue interest payments made up to such prepayment date. Under the RIFA the Company shall pay to NovaQuest up to a specified maximum amount (“Payment Cap”) of (a) $ 100.0 million, if the payment is made on or before December 31, 2028; (b) $ 112.5 million, if the payment is made on or after January 1, 2029, but on or before December 31, 2029; or (c) $ 125.0 million, if the payment is made after January 1, 2030. After January 1, 2028, if the product (as defined) is not commercialized for a consecutive twelve-month period, then, the payments owed under the RIFA by the Company to NovaQuest for each fiscal year shall be the greater of: (i) the amount which would otherwise be due pursuant to revenue interest payments terms; or (ii) $ 10.0 million. Before December 31, 2028, if the sum of all payments under the RIFA paid to NovaQuest, does not equal or exceed $ 62.5 million, then the Company shall pay NovaQuest the difference of these two amounts by no later than March 1, 2029. If, by no later than December 31, 2030, the sum of all payments under the RIFA paid to NovaQuest does not equal or exceed $ 125.0 million, then the Company shall pay NovaQuest the difference of these two amounts by no later than March 1, 2031. NovaQuest will retain this entitlement until it has reached the Payment Cap, at which point 100 % of such revenue interest on future global net sales of Astellas will revert to the Company. Over the course of the RIFA, the effective interest rate is affected by the amount and timing of drug product revenue and revenue from milestone payments recognized, the changes in the timing of forecasted drug product revenue and revenue from milestone payments, and the timing of the Company’s payments to NovaQuest. On a quarterly basis, the Company reassesses the expected total revenue and the timing of such revenue, recalculates the amortization of debt discount and transactions costs and effective interest rate, and adjusts the accounting prospectively as needed. The Company’s estimated effective annual interest rate was 19.64 % for the three months ended March 31, 2023. The following table summarizes the activity of the liability related to sale of future revenues for the three months ended March 31, 2023: Three Months Ended Liability related to sale of future revenues - beginning balance $ 49,333 Interest expense recognized 2,249 Liability related to sale of future revenues - ending balance 51,582 Less: Current portion classified to accrued and other current liabilities ( 3,212 ) Liability related to sale of future revenues, non-current $ 48,370 During the three months ended March 31, 2023 , the Company recognized, under Astellas Agreements, development revenue of $ 1.6 million and drug product revenue of $ 2.1 million. See Note 2, Collaboration Agreements, License Agreement and Revenue , for details. During the three months ended March 31, 2023 , the Company recognized the related non-cash interest expense of $ 2.2 million. Based on the current estimates of drug product revenue and revenue from milestone payments under the Astellas Agreements, and taking into the consideration of the terms discussed above, the Company anticipates to reach a Payment Cap up to $ 125.0 million by 2031. |
At-the-Market Program
At-the-Market Program | 3 Months Ended |
Mar. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
At-the-Market Program | 7. At-the-Market Program On February 27, 2023, the Company entered into an Amended and Restated Equity Distribution Agreement (the “at-the-market agreement”) with Goldman Sachs & Co., LLC and BofA Securities, Inc. (each a “Sales Agent”), which amended and restated its Equity Distribution Agreement with Goldman Sachs & Co., LLC, dated August 8, 2022, to add BofA Securities, Inc. as an additional Sales Agent under that agreement. Under the at-the-market agreement, the Company may issue and sell, from time to time and through the Sales Agents, shares of its common stock having an aggregate offering price of up to $ 200.0 million (the “ATM Program”). For the three months ended March 31, 2023 , the Company sold 1,541,579 shares under the ATM Program, for approximately $ 31.1 million, net of commissions to Sales Agents, at a weighted-average offering prices per share of $ 20.25 , of which $ 30.8 million was received in cash during the same period. The remainder of the net proceeds was recorded as other receivables and included in prepaid expenses and other current assets in the condensed consolidated balance sheet as of March 31, 2023 and received in April 2023. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 8. Income Taxes Provisions for income tax for the three months ended March 31, 2023 and 2022 were primarily due to foreign taxes. Based upon the weight of available evidence, which includes its historical operating performance, reported cumulative net losses since inception, the Company has established and continues to maintain a full valuation allowance against its net deferred tax assets as it does not currently believe that realization of those assets is more likely than not. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2023 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 9. Related Party Transactions Astellas is an equity investor in the Company and is considered a related party. The Company recorded license and development revenue related to collaboration agreements with Astellas of $ 1.6 million and $ 27.8 million for the three months ended March 31, 2023 and 2022 , respectively. The Company also recorded drug product revenue from Astellas of $ 2.1 million and $ 7.6 million for the three months ended March 31, 2023 and 2022, respectively. See Note 2, Collaboration Agreements, License Agreement and Revenues , for details. The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three months ended March 31, 2023 and 2022. As of March 31, 2023 and December 31, 2022 , accounts receivable from Astellas were $ 1.6 million and $ 1.5 million, respectively. As of March 31, 2023 and December 31, 2022 , total deferred revenue from Astellas was $ 23.4 million and $ 40.3 million, respectively. As of March 31, 2023, the amounts due to Astellas, included in accounts payable, accrued and other current liabilities, and other long-term liabilities, totaled $ 78.7 million. As of December 31, 2022 , the amount due to Astellas, included in accrued and other current liabilities, was $ 63.9 million. Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1 % of Falikang’s equity. See Note 3, Equity method investment - Variable Interest Entity , for details. The net product revenue from Falikang was $ 21.4 million and $ 16.2 million for the three months ended March 31, 2023 and 2022, respectively. See the Product Revenue, Net section in Note 2, Collaboration Agreements, License Agreement and Revenues , for details. The investment income in Falikang was $ 0.8 million and $ 0.3 million for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023 and December 31, 2022, the Company’s equity method investment in Falikang was $ 5.9 million and $ 5.1 million , respectively. See Note 3, Variable Interest Entity , for details. The other income from Falikang was immaterial for each of the three months ended March 31, 2023 and 2022. As of March 31, 2023 and December 31, 2022 , accounts receivable, net, from Falikang, were $ 9.9 million and $ 10.5 million, respectively. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 10. Commitments and Contingencies Contract Obligations As of March 31, 2023 , the Company had outstanding total non-cancelable purchase obligations of $ 51.9 million, including $ 22.4 million for manufacture and supply of pamrevlumab, $ 4.1 million for manufacture and supply of roxadustat, and $ 25.4 million for other purchases and programs. The Company expects to fulfill its commitments under these agreements in the normal course of business, and as such, no liability has been recorded. Some of the Company’s license agreements provide for periodic maintenance fees over specified time periods, as well as payments by the Company upon the achievement of development, regulatory and commercial milestones. As of March 31, 2023 , future milestone payments for research and preclinical stage development programs consisted of up to approximately $ 697.9 million in total potential future milestone payments under the Company’s license agreements with HiFiBiO (for Gal-9 and CCR8), Medarex, Inc. and others. These milestone payments generally become due and payable only upon the achievement of certain developmental, clinical, regulatory and/or commercial milestones. The event triggering such payment or obligation has not yet occurred. As of March 31, 2023, the Company had $ 86.8 million of operating lease liabilities. In addition, see Note 6, Liability Related to Sale of Future Revenues for details of the related obligation. Legal Proceedings and Other Matters From time to time, the Company is a party to various legal actions, both inside and outside the U.S., arising in the ordinary course of its business or otherwise. The Company accrues amounts, to the extent they can be reasonably estimated, that the Company believes will result in a probable loss (including, among other things, probable settlement value) to adequately address any liabilities related to legal proceedings and other loss contingencies. A loss or a range of loss is disclosed when it is reasonably possible that a material loss will incur and can be estimated, or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. The Company did not have any material accruals for any active legal action in its condensed consolidated balance sheet as of March 31, 2023, as the Company could not predict the ultimate outcome of these matters, or reasonably estimate the potential exposure. Between April 2021 and May 2021, five putative securities class action complaints were filed against FibroGen and certain of its current and former executive officers (collectively, the “Defendants”) in the U.S. District Court for the Northern District of California. The lawsuits allege that Defendants violated the Securities Exchange Act of 1934 by making materially false and misleading statements regarding FibroGen’s Phase 3 clinical studies data and prospects for U.S. Food and Drug Administration approval. On August 30, 2021, the Court consolidated the actions and appointed a group of lead plaintiffs. Plaintiffs filed their consolidated amended complaint on October 29, 2021 and a corrected consolidated amended complaint on November 19, 2021 (the “Complaint”). The Complaint alleges false and misleading statements between December 2018 and June 2021 and seeks to represent a class of persons or entities that purchased FibroGen securities between December 20, 2018 and July 15, 2021. On July 15, 2022, the court issued an order denying Defendants’ motions to dismiss. Defendants answered the Complaint on September 13, 2022 and discovery is ongoing. On January 27, 2023, Plaintiffs filed a motion for class certification. Defendants’ opposition to the motion for class certification is due May 12, 2023. On July 30, 2021, a purported shareholder derivative (the “California Federal Derivative”) complaint was filed in the U.S. District Court for the Northern District of California. The California Federal Derivative complaint names as defendants FibroGen’s current and former officers and directors, as well as FibroGen as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaint. The California Federal Derivative complaint seeks unspecified damages, attorneys’ fees, and other costs. On December 27, 2021, a second purported shareholder derivative (the “Delaware Federal Derivative”) complaint was filed in the U.S. District Court for the District of Delaware. The Delaware Federal Derivative complaint names FibroGen’s current and former officers and directors as defendants, as well as FibroGen as nominal defendant, and asserts state and federal claims based on some of the same alleged misstatements as the securities class action complaint, as well as allegations of insider trading against certain defendants. The Delaware Federal Derivative complaint seeks unspecified damages, attorneys’ fees, and other costs. On April 14, 2022, a third purported shareholder derivative (the “Delaware Chancery Derivative”) complaint was filed in the Delaware Court of Chancery. The Delaware Chancery Derivative complaint names substantially the same defendants as the other purported shareholder derivative actions and asserts similar claims based upon similar allegations. The Delaware Chancery Derivative complaint seeks unspecified damages, attorneys’ fees, and other costs. All three derivative actions have been stayed pending resolution of any motions for summary judgment in the securities class action. The Company believes that the claims are without merit and it intends to vigorously defend against them. However, any litigation is inherently uncertain, and any judgment or injunctive relief entered against FibroGen or any adverse settlement could materially and adversely impact its business, results of operations, financial condition, and prospects. In the fourth quarter of 2021, the Company received a subpoena from the SEC requesting documents related to roxadustat’s pooled cardiovascular safety data. The Company is fully cooperating with the SEC. The Company cannot predict with any degree of certainty the outcome of the SEC’s investigation or determine the extent of any potential liabilities. The Company also cannot predict whether there will be any loss as a result of the investigation nor can it provide an estimate of the possible loss or range of loss. Any adverse outcome in this matter or any related proceeding could expose the Company to substantial damages, penalties, or reputational harm that may have a material adverse impact on the Company’s business, results of operations, financial condition, growth prospects, and price of its common stock. Between August 3, 2022 and August 4, 2022, the Company’s Board of Directors received three litigation demands from purported shareholders of the Company, asking the Board of Directors to investigate and take action against certain current and former officers and directors of the Company for alleged wrongdoing based on the same allegations in the pending derivative and securities class action lawsuits. On March 27, 2023, the Company’s Board of Directors received another litigation demand from a purported shareholder of the Company, seeking similar action as the other litigation demands. The Company may in the future receive such additional demands. Starting in October 2021, certain challenges have been filed with the China National Intellectual Property Administration against patents which claim a crystalline form of roxadustat. Final resolution of such proceedings will take time and the Company could not predict the ultimate outcome, or reasonably estimate the potential exposure. Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business, including for example, service, manufacturing and collaboration agreements. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with intellectual property infringement claims by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the extent permissible under applicable law. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the estimated fair value of these arrangements is minimal. |
Subsequent Event
Subsequent Event | 3 Months Ended |
Mar. 31, 2023 | |
Subsequent Events [Abstract] | |
Subsequent Event | 11. Subsequent Event Debt Financing Agreement On April 29, 2023, FibroGen entered into a financing agreement (“Financing Agreement”) with investment funds managed by Morgan Stanley Tactical Value, as lenders (the “Lenders”), and Wilmington Trust, National Association, as the administrative agent (the “Administrative Agent”), providing for senior secured term loan facilities consisting of (i) a $ 75.0 million initial term loan (the “Initial Term Loan”), (ii) a $ 37.5 million delayed draw term loan that will be funded upon the achievement of certain clinical development milestones (“Delayed Draw Term Loan 1”) and, (iii) an uncommitted delayed draw term loan of up to $ 37.5 million to be funded at the Lenders sole discretion, (“Delayed Draw Term Loan 2” and, together with the Initial Term Loan and Delayed Draw Term Loan 1, the “Term Loans”). Pursuant to the Financing Agreement, the Lenders (i) shall fund the Initial Term Loan by May 8, 2023, (ii) shall fund the Delayed Draw Term Loan 1 within 24 business days from the date of achievement of certain clinical development milestones but no later than August 31, 2023 and, (iii) at their discretion, shall provide Delayed Draw Term Loan 2 on or prior to August 31, 2023, whether or not such clinical development milestones are achieved. The Term Loans shall accrue interest at a rate of 14.0 % per annum, payable monthly in arrears. The Term Loans shall mature on May 8, 2026. The Term Loans will not be subject to amortization payments. The Company is permitted to prepay the Term Loans from time to time, in whole or in part, subject to payment of a make-whole amount equal to the unpaid principal amount of the portion of the Term Loans being repaid or prepaid, plus accrued and unpaid interest of the portion of the Term Loans being repaid or prepaid, plus an amount equal to the remaining scheduled interest payments due on such portion of the Term Loans being repaid or prepaid as if such Term Loans were to remain outstanding until the scheduled maturity date. During the term of the Term Loans, the Company is required to maintain a minimum balance of $ 30.0 million of unrestricted cash and cash equivalents held in accounts in the United States, tested monthly on each interest payment date (after netting the monthly interest payment then due). In addition, while any portion of the Term Loans or any other obligations under the Financing Agreement remain outstanding, the Company must comply with certain customary affirmative and negative covenants set forth in the Financing Agreement and related loan documents, including, without limitation, restrictions or limitations on: incurrence of further indebtedness or liens, acquisitions and other investments, breach or material default under certain material contracts, dividends, distributions and stock buy-backs, negative pledges, sales, transfers, licenses or other disposition of assets (including core intellectual property), prepayment of other indebtedness, and transactions with affiliates, in each case, subject to thresholds and exceptions set forth in the Financing Agreement and related loan documents. The Financing Agreement provides for customary events of default triggers, including, without limitation, non-payment, breach of covenants (including the minimum cash covenant described above), material misrepresentation, cross-default to other material indebtedness of the Company or its subsidiaries (or the imposition of a material event of default fee or similar payment under a royalty monetization transaction), commencement of voluntary or involuntary bankruptcy proceedings, material judgments, change of control, invalidity of loan documents, certain ERISA events, certain regulatory events and failure to draw any portion of the Delayed Draw Term Loan 1 when funded by the Lenders. Upon an event of default, the Administrative Agent may, and at the direction of the majority Lenders shall, accelerate all outstanding obligations of the Company under the Financing Agreement and related loan documents, terminate all outstanding funding commitments and/or exercise remedies available at law or equity or under contract for secured creditors. The Term Loans and all other obligations of the Company under the Financing Agreement and related loan documents are guaranteed by each of the Company’s current and future, direct and indirect, subsidiaries, with certain exceptions (including an exclusion for any Chinese subsidiary of the Company). The Term Loans are secured by substantially all assets of the Company and the guarantors, subject to customary exceptions. Exclusive License and Option to Acquire Fortis Therapeutics On May 5, 2023, the Company entered into an exclusive option agreement to acquire Fortis Therapeutics (“Fortis”) with its novel Phase 1 antibody-drug conjugate, FOR46, that targets a novel epitope on CD46 preferentially expressed on certain cancer cells. FOR46 is in development for the treatment of metastatic castration-resistant prostate cancer with potential applicability in other solid tumors and hematologic malignancies. Pursuant to an evaluation agreement entered into with Fortis concurrent with the option agreement, FibroGen has exclusively licensed FOR46 and will control and fund future research, development, including a Phase 2 clinical study sponsored by FibroGen, and manufacturing of FOR46 during the four-year option period. As part of the clinical development strategy, FibroGen will continue the work to develop a PET-based biomarker utilizing a radiolabeled version of the targeting antibody (“PET46”) for patient selection. FibroGen will pay Fortis $ 5.0 million during the four-year option period in support of their continued development obligations. If FibroGen exercises the option to acquire Fortis, it will pay Fortis $ 80.0 million, and thereafter, Fortis would be eligible to receive from FibroGen up to $ 200.0 million in contingent payments associated with the achievement of various regulatory approvals. If FibroGen acquires Fortis, it would also be responsible to pay UCSF, an upstream licensor to Fortis, development milestone fees and a single digit royalty on net sales of therapeutic or diagnostic products arising from the collaboration. If FibroGen chooses not to acquire Fortis, its exclusive license to FOR46 would expire. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Description of Operations | Description of Operations FibroGen, Inc. (“FibroGen” or the “Company”) is headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People’s Republic of China (“China”). FibroGen is a leading biopharmaceutical company discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (“HIF”) biology, 2-oxoglutarate enzymology, and connective tissue growth factor to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor, is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis, locally advanced unresectable pancreatic cancer and Duchenne muscular dystrophy. To date, the Company has retained exclusive worldwide rights for pamrevlumab. Roxadustat is an oral small molecule inhibitor of HIF prolyl hydroxylase activity. Roxadustat (爱瑞卓 ® , EVRENZO TM ) is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease for patients who are on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development for anemia associated with myelodysplastic syndromes, in the United States (“U.S.”) and Europe, and chemotherapy-induced anemia in China. The Company has a pipeline of late-stage clinical programs as well as preclinical drug candidates at various stages of development that include both small molecules and biologics. FibroGen’s goal is to build a diversified pipeline with novel drugs that will address unmet patient needs in oncology, immunology, and fibrosis. |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The condensed consolidated financial statements include the accounts of FibroGen, its wholly-owned subsidiaries and its majority-owned subsidiaries, FibroGen Europe Oy and FibroGen China Anemia Holdings, Ltd. All inter-company transactions and balances have been eliminated in consolidation. For any variable interest entity (“VIE”) for which FibroGen is not the primary beneficiary, the Company uses the equity method of accounting. The Company operates as one reportable segment — the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The unaudited condensed consolidated financial statements and related disclosures have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) applicable to interim financial reporting and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements. The financial information included herein should be read in conjunction with the consolidated financial statements and related notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 , filed on February 27, 2023 (“2022 Form 10-K”). |
Use of Estimates | Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue and deferred revenue, specifically, estimates in variable consideration for drug product sales, and estimates in transaction price per unit for the China performance obligation. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. In the Company’s opinion, the accompanying unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair statement of its financial position, results of operations and cash flows for the interim periods presented. |
Net Loss per Share | Net Loss per Share Potential common shares that would have the effect of increasing diluted earnings per share are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted earnings per share. The Company reported a net loss for the three months ended March 31, 2023 and 2022. Therefore, dilutive common shares are not assumed to have been issued since their effect is anti-dilutive for these periods. Diluted weighted average shares excluded the following potential common shares related to s tock options, service-based restricted stock units (“RSUs”), performance-based RSUs (“PRSUs”), total shareholder return (“TSR”) awards and shares to be purchased under the 2014 Employee Stock Purchase Plan (“ESPP”) for the periods presented as they were anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Employee stock options 7,578 9,484 RSUs, PRSUs and TSR awards 2,762 2,196 ESPP 362 473 10,702 12,153 |
Risks and Uncertainties | Risks and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the results of clinical trials and the achievement of milestones, research developments, actions by regulatory authorities, market acceptance of the Company’s product candidates, competition from other products and larger companies, the liquidity and capital resources of the Company, intellectual property protection for the Company’s proprietary technology, strategic relationships, and dependence on key individuals, suppliers, clinical organization, and other third parties. |
Collaboration Agreements, License Agreement and Revenues | Astellas Agreements Astellas Japan Agreement In June 2005, the Company entered into a collaboration agreement with Astellas for the development and commercialization (but not manufacture) of roxadustat for the treatment of anemia in Japan (“Astellas Japan Agreement”). Under this agreement, Astellas agreed to pay license fees, other upfront consideration and various milestone payments, totaling $ 172.6 million . The Astellas Japan Agreement also provides for tiered payments based on net sales of product (as defined) in the low 20% range of the list price published by Japan’s Ministry of Health, Labour and Welfare, adjusted for certain elements, after commercial launch. The aggregate amount of consideration received through March 31, 2023 totaled $ 105.1 million , excluding drug product revenue that is discussed under the Drug Product Revenue section below. |
Product Revenue, Net | Product Revenue, Net Product revenue, net from the sales of roxadustat commercial product in China was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Direct Sales: Gross revenue $ 3,060 $ 2,830 Discounts and rebates ( 273 ) ( 175 ) Sales returns 2 3 Direct sales revenue, net 2,789 2,658 Sales to Falikang: Gross transaction price 34,249 22,726 Profit share ( 14,988 ) ( 8,849 ) Net transaction price 19,261 13,877 Decrease in deferred revenue 2,111 2,346 Sales to Falikang revenue, net 21,372 16,223 Total product revenue, net $ 24,161 $ 18,881 Direct Sales Product revenue from direct roxadustat product sales to distributors in China is recognized in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those products, net of various sales rebates and discounts. The total discounts and rebates were immaterial for the periods presented. Due to the Company’s legal right to offset, at each balance sheet date, the rebates and discounts are presented as reductions to gross accounts receivable from the distributor, or as a current liability to the distributor to the extent that the total amount exceeds the gross accounts receivable or when the Company expects to settle the discount in cash. The Company’s legal right to offset is calculated at the individual distributor level. The contract liabilities were included in accrued and other current liabilities in the condensed consolidated balance sheet and were immaterial as of March 31, 2023 and December 31, 2022, respectively. The rebates and discounts reflected as reductions to gross accounts receivable for direct sales were immaterial as of March 31, 2023 and December 31, 2022, respectively. Sales to Falikang – China Performance Obligation Substantially all direct roxadustat product sales to distributors in China are made by Falikang. FibroGen Beijing manufactures and supplies commercial product to Falikang. The net transfer price for FibroGen Beijing’s product sales to Falikang is based on a gross transfer price, which is adjusted to account for the 50/50 profit share for the period. The roxadustat sales to Falikang marked the beginning of the Company’s China performance obligation under the Company’s agreements with AstraZeneca . Product revenue is based on the transaction price of the China performance obligation. Revenue is recognized when control of the product is transferred to Falikang, in an amount that reflects the allocation of the transaction price to the performance obligation satisfied during the reporting period. Any net transaction price in excess of the revenue recognized is added to the deferred balance to date, and will be recognized in future periods as the performance obligation is satisfied. Periodically, the Company updates its assumptions such as total sales quantity, performance period and other inputs including foreign currency translation impact, among others. Following updates to its estimates, the Company recognized $ 2.1 million and $ 2.3 million from the previously deferred revenue of the China performance obligation during the three months ended March 31, 2023 and 2022, respectively. The product revenue recognized for the three months ended March 31, 2023 included a decrease in revenue of $ 0.3 million resulting from changes to estimated variable consideration in the current period relating to performance obligations satisfied in previous periods. The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands): Balance at Additions Recognized as Revenue Currency Balance at Product revenue - AstraZeneca China $ ( 175,646 ) $ ( 20,889 ) $ 21,372 $ ( 163 ) $ ( 175,326 ) Deferred revenue includes amounts allocated to the China performance obligation under the AstraZeneca arrangement as revenue recognition associated with this unit of accounting is tied to the commercial launch of the products within China and to when the control of the manufactured commercial products is transferred to AstraZeneca. As of March 31, 2023 , approximately $ 22.5 million of the above deferred revenue related to the China unit of accounting was included in short-term deferred revenue, which represents the amount of deferred revenue associated with the China unit of accounting that is expected to be recognized within the next 12 months, associated with the commercial sales in China. Due to the Company’s legal right to offset, at each balance sheet date, the rebates and discounts, mainly related to profit sharing, are presented as reductions to gross accounts receivable from Falikang, which was $ 2.2 million and $ 0.5 million as of March 31, 2023 and December 31, 2022 , respectively. |
Drug Product Revenue | Drug Product Revenue Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Astellas Japan Agreement $ 1,732 $ 7,594 Astellas Europe Agreement 377 — Drug product revenue $ 2,109 $ 7,594 Astellas Japan Agreement During the three months ended March 31, 2023, the Company updated its estimate of variable consideration related to the API shipments fulfilled under the terms of Astellas Japan Amendment, and accordingly recorded adjustments to the drug product revenue of $ 1.7 million. Specifically, the change in estimated variable consideration was based on the API held by Astellas at period end, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, and estimated yield from the manufacture of bulk product tablets, among others. During the three months ended March 31, 2022, the Company fulfilled a shipment obligation under the terms of Astellas Japan Amendment, and recognized related drug product revenue of $ 9.8 million in the same period. In addition, the Company updated its estimate of variable consideration related to the API shipments fulfilled under the terms of Astellas Japan Amendment, and recorded a reduction to the drug product revenue of $ 2.2 million during the first quarter of 2022. Specifically, the change in estimated variable consideration was based on the API held by Astellas at period end, adjusted to reflect the changes in the estimated bulk product strength mix intended to be manufactured by Astellas, estimated cost to convert the API to bulk product tablets, and estimated yield from the manufacture of bulk product tablets, among others. As of March 31, 2023, t he balances related to the API price true-up under the Astellas Japan Agreement were $ 3.2 million in accrued liabilities and $ 1.6 million in other long-term liabilities, representing the Company’s best estimate of the timing for these amounts to be paid. As of December 31, 2022, the related balance in accrued liabilities was $ 6.5 million. Astellas Europe Agreement The Company transferred bulk drug product for commercial purposes under the terms of the Astellas Europe Agreement and the Astellas EU Supply Agreement in the prior years, and recognized the related fully burdened manufacturing costs as drug product revenue in the respective periods and recorded the constrained transaction price in deferred revenue due to a high degree of uncertainty associated with the variable consideration for revenue recognition purposes. During the first quarter of 2022, the Company updated its estimate of variable consideration related to the bulk drug product transferred in prior years. Specifically, the change in estimated variable consideration was based on the bulk drug product held by Astellas at the period end, adjusted to reflect the changes in the estimated transfer price, forecast information, shelf-life estimates and other items. As a result, the Company reclassified the related deferred revenue to accrued liabilities during the year ended December 31, 2022. As of December 31, 2022, the related balance was $ 57.4 million in accrued liabilities. Further during the three months ended March 31, 2023 , the Company reclassified $ 16.6 million from the related deferred revenue to accrued liabilities. As of March 31, 2023, the balances related to the bulk drug product price true-up under the Astellas Europe Agreement and the Astellas EU Supply Agreement were $ 57.5 million in accounts payable and $ 16.4 million in a ccrued liabilities, representing the Company’s best estimate that these amounts will be paid within the next 12 months. The Company recognized royalty revenue of $ 0.4 million as drug product revenue from the deferred revenue under the Astellas Europe Agreement during the three months ended March 31, 2023. It is the Company’s best estimate that the remainder of the deferred revenue will be recognized as revenue when uncertainty is resolved, based on the performance of roxadustat product sales in the Astellas territory. The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands): Balance at Additions Recognized as Revenue Reclassified to Accrued Liability / Accounts Payable Balance at Drug product revenue - deferred revenue: Astellas Europe Agreement $ ( 40,303 ) $ — $ 377 $ 16,552 $ ( 23,374 ) AstraZeneca U.S./RoW Agreement There was no shipment of bulk drug product to AstraZeneca as commercial supply under the terms of the AstraZeneca Master Supply Agreement during the three months ended March 31, 2023 and 2022. During the first quarter of 2022, the Company evaluated the current developments in the U.S. market, and updated its estimates of variable consideration associated with bulk drug product shipments to AstraZeneca in prior years as commercial supply. As a result, the Company reclassified $ 11.2 million from the related deferred revenue to accrued liabilities during the year ended December 31, 2022. As of each of March 31, 2023 and December 31, 2022, the related balance in accrued liabilities was $ 11.2 million, representing the Company’s best estimate that this amount will be paid within the next 12 months . |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share | Diluted weighted average shares excluded the following potential common shares related to s tock options, service-based restricted stock units (“RSUs”), performance-based RSUs (“PRSUs”), total shareholder return (“TSR”) awards and shares to be purchased under the 2014 Employee Stock Purchase Plan (“ESPP”) for the periods presented as they were anti-dilutive (in thousands): Three Months Ended March 31, 2023 2022 Employee stock options 7,578 9,484 RSUs, PRSUs and TSR awards 2,762 2,196 ESPP 362 473 10,702 12,153 |
Collaboration Agreements, Lic_2
Collaboration Agreements, License Agreement and Revenues (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net | Product revenue, net from the sales of roxadustat commercial product in China was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Direct Sales: Gross revenue $ 3,060 $ 2,830 Discounts and rebates ( 273 ) ( 175 ) Sales returns 2 3 Direct sales revenue, net 2,789 2,658 Sales to Falikang: Gross transaction price 34,249 22,726 Profit share ( 14,988 ) ( 8,849 ) Net transaction price 19,261 13,877 Decrease in deferred revenue 2,111 2,346 Sales to Falikang revenue, net 21,372 16,223 Total product revenue, net $ 24,161 $ 18,881 |
Roll-forward of Related Contract Liabilities | The following table includes a roll-forward of the related deferred revenue that is considered as a contract liability (in thousands): Balance at Additions Recognized as Revenue Currency Balance at Product revenue - AstraZeneca China $ ( 175,646 ) $ ( 20,889 ) $ 21,372 $ ( 163 ) $ ( 175,326 ) |
Schedule of Drug Product Revenue | Drug product revenue from commercial-grade active pharmaceutical ingredient (“API”) or bulk drug product sales to Astellas and AstraZeneca was as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, 2023 2022 Astellas Japan Agreement $ 1,732 $ 7,594 Astellas Europe Agreement 377 — Drug product revenue $ 2,109 $ 7,594 |
Summary of Amounts Recognized as Revenue | Amounts recognized as revenue under the Eluminex were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Eluminex License revenue $ 6,000 $ — Other revenue - contract manufacturing $ 235 $ 762 |
Drug Product Revenue [Member] | |
Roll-forward of Related Contract Liabilities | The following table includes a roll-forward of the above-mentioned deferred revenues that are considered as contract liabilities related to drug product (in thousands): Balance at Additions Recognized as Revenue Reclassified to Accrued Liability / Accounts Payable Balance at Drug product revenue - deferred revenue: Astellas Europe Agreement $ ( 40,303 ) $ — $ 377 $ 16,552 $ ( 23,374 ) |
Japan [Member] | |
Summary of License Revenue and Development Revenue Recognized under Agreement | Amounts recognized as license revenue and development revenue under the Astellas Japan Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Astellas Japan Agreement License revenue $ — $ — Development revenue $ 95 $ 32 |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net | The transaction price related to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the Astellas Japan Agreement (in thousands): Astellas Japan Agreement Total Consideration License $ 100,347 Development revenue 16,977 Total license and development revenue $ 117,324 |
Europe [Member] | |
Summary of License Revenue and Development Revenue Recognized under Agreement | Amounts recognized as license revenue and development revenue under the Astellas Europe Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 Astellas Europe Agreement License revenue $ — $ 22,590 Development revenue $ 1,529 $ 5,148 |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net | The transaction price related to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the Astellas Europe Agreement as follows (in thousands): Astellas Europe Agreement Total Consideration License $ 618,975 Development revenue 281,794 Total license and development revenue $ 900,769 |
U.S./RoW and China [Member] | |
Summary of License Revenue and Development Revenue Recognized under Agreement | Amounts recognized as license revenue and development revenue under the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement were as follows for the three months ended March 31, 2023 and 2022 (in thousands): Three Months Ended March 31, Agreement Performance Obligation 2023 2022 AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement License revenue $ — $ — Development revenue 2,032 5,819 |
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations and Product Revenue Net | The transaction price relat ed to consideration received through March 31, 2023 and accounts receivable has been allocated to each of the following performance obligations under the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement, along with any associated deferred revenue as follows (in thousands): AstraZeneca U.S./RoW Agreement and Cumulative Revenue Deferred Revenue at Total Consideration License $ 341,844 $ — $ 341,844 Co-development, information sharing & 617,670 — 617,670 China performance obligation * 128,106 175,326 303,432 Total license and development revenue $ 1,087,620 $ 175,326 ** $ 1,262,946 * China performance obligation revenue is recognized as product revenue, as described under Product Revenue, Net section below. ** Contract assets and liabilities related to rights and obligations in the same contract are recorded net on the consolidated balance sheets. As of March 31, 2023, deferred revenue included $ 156.2 million related to the AstraZeneca U.S./RoW Agreement and AstraZeneca China Agreement, which represents the net of $ 175.3 million of deferred revenue presented above and a $ 19.1 million unbilled co-development revenue under the AstraZeneca China Amendment. |
Equity method investment - Va_2
Equity method investment - Variable Interest Entity (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Acquisition And Variable Interest Entity [Abstract] | |
Summary of Equity Method Investment | The Company’s equity method investment in Falikang was as follows (in thousands): Entity Ownership Percentage Balance at Share of Net Income Currency Balance at Falikang 51.1 % $ 5,061 $ 796 $ 27 $ 5,884 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Disclosures [Abstract] | |
Fair Values of Financial Assets Measured on Recurring Basis | The fair values of the Company’s financial assets that are measured on a recurring basis are as follows (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 42,740 $ — $ — $ 42,740 Corporate bonds — 41,304 — 41,304 Commercial paper — 42,970 — 42,970 U.S. government bonds 57,141 14,425 — 71,566 Agency bonds — 9,075 — 9,075 Asset-backed securities — 2,484 — 2,484 Total $ 99,881 $ 110,258 $ — $ 210,139 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 19,881 $ — $ — $ 19,881 Corporate bonds — 82,008 — 82,008 Commercial paper — 57,381 — 57,381 U.S. government bonds 98,972 12,373 — 111,345 Agency bonds — 11,468 — 11,468 Asset-backed securities — 2,474 — 2,474 Foreign government bonds — 4,980 — 4,980 Convertible promissory note — — 1,000 1,000 Total $ 118,853 $ 170,684 $ 1,000 $ 290,537 |
Balance Sheet Components (Table
Balance Sheet Components (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Schedule of Cash and Cash Equivalents | Cash and cash equivalents consisted of the following (in thousands): March 31, 2023 December 31, 2022 Cash $ 145,810 $ 135,819 Money market funds 42,740 19,881 Total cash and cash equivalents $ 188,550 $ 155,700 |
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments | The Company’s investments consist primarily of available-for-sale debt investments. The amortized cost, gross unrealized holding gains or losses, and fair value of the Company’s investments by major investments type are summarized in the tables below (in thousands): March 31, 2023 Amortized Cost Gross Unrealized Gross Unrealized Estimated Corporate bonds $ 41,760 $ 1 $ ( 457 ) $ 41,304 Commercial paper 42,970 — — 42,970 U.S. government bonds 72,130 1 ( 565 ) 71,566 Agency bonds 9,183 — ( 108 ) 9,075 Asset-backed securities 2,491 — ( 7 ) 2,484 Total investments $ 168,534 $ 2 $ ( 1,137 ) $ 167,399 December 31, 2022 Amortized Cost Gross Unrealized Gross Unrealized Estimated Corporate bonds $ 83,080 $ — $ ( 1,072 ) $ 82,008 Commercial paper 57,381 — — 57,381 U.S. government bonds 112,547 5 ( 1,207 ) 111,345 Agency bonds 11,690 — ( 222 ) 11,468 Asset-backed securities 2,484 — ( 10 ) 2,474 Foreign government bonds 5,007 — ( 27 ) 4,980 Convertible promissory note 1,000 — — 1,000 Total investments $ 273,189 $ 5 $ ( 2,538 ) $ 270,656 |
Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position | The following table summarizes, for all available for sale securities in an unrealized loss position, the fair value and gross unrealized loss by length of time the security has been in a continual unrealized loss position (in thousands): March 31, 2023 Less than 12 Months 12 Months or More Total Estimated Gross Unrealized Estimated Gross Unrealized Estimated Gross Unrealized Corporate bonds $ 2,469 $ ( 7 ) $ 36,084 $ ( 450 ) $ 38,553 $ ( 457 ) U.S. government bonds 4,955 ( 1 ) 43,794 ( 564 ) 48,749 ( 565 ) Agency bonds — — 9,075 ( 108 ) 9,075 ( 108 ) Asset-backed securities 2,483 ( 7 ) — — 2,483 ( 7 ) Total $ 9,907 $ ( 15 ) $ 88,953 $ ( 1,122 ) $ 98,860 $ ( 1,137 ) December 31, 2022 Less than 12 Months 12 Months or More Total Estimated Gross Unrealized Estimated Gross Unrealized Estimated Gross Unrealized Corporate bonds $ 6,738 $ ( 147 ) $ 75,270 $ ( 925 ) $ 82,008 $ ( 1,072 ) U.S. government bonds 22,326 ( 13 ) 67,909 ( 1,194 ) 90,235 ( 1,207 ) Agency bonds — — 11,468 ( 222 ) 11,468 ( 222 ) Asset-backed securities 2,474 ( 10 ) — — 2,474 ( 10 ) Foreign government bonds - — 4,980 ( 27 ) 4,980 ( 27 ) Total $ 31,538 $ ( 170 ) $ 159,627 $ ( 2,368 ) $ 191,165 $ ( 2,538 ) |
Schedule of Inventory | Inventories consisted of the following (in thousands): March 31, 2023 December 31, 2022 Raw materials $ 1,226 $ 1,241 Work-in-progress $ 37,273 36,003 Finished goods $ 3,957 3,192 Total inventories $ 42,456 $ 40,436 |
Schedule of Accrued and Other Current Liabilities | Accrued and other current liabilities consisted of the following (in thousands): March 31, 2023 December 31, 2022 Preclinical and clinical trial accruals $ 42,953 $ 57,780 API and bulk drug product price true-up 30,758 75,055 Payroll and related accruals 12,230 22,562 Accrued co-promotion expenses - current 36,688 36,677 Roxadustat profit share to AstraZeneca 7,311 7,280 Property taxes and other taxes 8,041 7,691 Professional services 8,354 5,480 Current portion of liability related to sale of future revenues 3,212 — Other 7,495 7,248 Total accrued and other current liabilities $ 157,042 $ 219,773 |
Liability Related to Sale of _2
Liability Related to Sale of Future Revenues (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Liability Related to Sale of Future Royalties [Abstract] | |
Schedule of Activity of Liability Related to Sale of Future Revenues | The following table summarizes the activity of the liability related to sale of future revenues for the three months ended March 31, 2023: Three Months Ended Liability related to sale of future revenues - beginning balance $ 49,333 Interest expense recognized 2,249 Liability related to sale of future revenues - ending balance 51,582 Less: Current portion classified to accrued and other current liabilities ( 3,212 ) Liability related to sale of future revenues, non-current $ 48,370 |
Significant Accounting Polici_4
Significant Accounting Policies - Additional Information (Detail) | 3 Months Ended |
Mar. 31, 2023 Segment | |
Accounting Policy [Line Items] | |
Number of reportable segment | 1 |
Significant Accounting Polici_5
Significant Accounting Policies - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from computation of net loss per share | 10,702 | 12,153 |
Employee stock options [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from computation of net loss per share | 7,578 | 9,484 |
RSUs, PRSUs and TSR awards [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from computation of net loss per share | 2,762 | 2,196 |
ESPP [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Anti-dilutive securities excluded from computation of net loss per share | 362 | 473 |
Collaboration Agreements, Lic_3
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($) | 1 Months Ended | 3 Months Ended | |||
Apr. 30, 2006 | Jun. 30, 2005 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total revenue | $ 36,161,000 | $ 60,827,000 | |||
Deferred Revenue | 16,495,000 | $ 12,739,000 | |||
Drug Product Revenue [Member] | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total revenue | 2,109,000 | 7,594,000 | |||
Japan [Member] | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Transaction price, variable consideration from estimated future co-development billing | 0 | ||||
Japan [Member] | Drug Product Revenue [Member] | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Total revenue | $ 1,700,000 | 9,800,000 | |||
Astellas Agreement [Member] | Japan [Member] | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Upfront, non-contingent and time-based payments received | $ 172,600,000 | ||||
Additional consideration based on net sales description | the low 20% range of the list price | ||||
Aggregate consideration received excluding drug product revenue | $ 105,100,000 | ||||
Changes in revenue from changes to estimated variable consideration | $ 0 | ||||
Astellas Agreement [Member] | Europe [Member] | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Upfront, non-contingent and time-based payments received | $ 745,000,000 | ||||
Additional consideration based on net sales description | low 20% range | ||||
Aggregate consideration received excluding drug product revenue | $ 685,000,000 | ||||
Transaction price, variable consideration from estimated future co-development billing | 5,800,000 | ||||
Percentage of joint development costs committed to fund | 50% | ||||
Transaction price and allocated to performance obligations | $ 25,000,000 | ||||
Changes in revenue from changes to estimated variable consideration | $ 0 |
Collaboration Agreements, Lic_4
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($) $ in Thousands | 3 Months Ended | |||
Jul. 30, 2013 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Total revenue | $ 36,161 | $ 60,827 | ||
Deferred Revenue | 16,495 | $ 12,739 | ||
Drug product revenue recognized | 36,161 | 60,827 | ||
Product Revenue, Net [Member] | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Total revenue | 24,161 | 18,881 | ||
Drug product revenue recognized | 24,161 | 18,881 | ||
Drug Product Revenue [Member] | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Total revenue | 2,109 | 7,594 | ||
Drug product revenue recognized | $ 2,109 | 7,594 | ||
AstraZeneca Agreements [Member] | U.S./RoW [Member] | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Upfront, non-contingent, non-refundable and time-based payments | $ 1,200,000 | |||
Additional consideration based on net sales description | low 20% range | |||
Aggregate consideration received excluding drug product revenue | $ 439,000 | |||
AstraZeneca Agreements [Member] | China [Member] | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Upfront, non-contingent, non-refundable and time-based payments | $ 376,700 | |||
Aggregate considerations received | 77,200 | |||
Direct Sales [Member] | Product Revenue, Net [Member] | ||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||
Total revenue | 2,789 | 2,658 | ||
Drug product revenue recognized | $ 2,789 | $ 2,658 |
Collaboration Agreements, Lic_5
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | $ 36,161 | $ 60,827 |
License Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 6,000 | 22,590 |
Development Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 3,891 | 11,762 |
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 0 | 0 |
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 0 | 22,590 |
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 95 | 32 |
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 1,529 | 5,148 |
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 0 | 0 |
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | $ 2,032 | $ 5,819 |
Collaboration Agreements, Lic_6
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Astellas Agreement [Member] | Japan [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | $ 117,324 | |
Astellas Agreement [Member] | Japan [Member] | Development Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | 16,977 | |
Astellas Agreement [Member] | Japan [Member] | License Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | 100,347 | |
Astellas Agreement [Member] | Europe [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | 900,769 | |
Astellas Agreement [Member] | Europe [Member] | Development Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | 281,794 | |
Astellas Agreement [Member] | Europe [Member] | License Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total Consideration | 618,975 | |
AstraZeneca Agreements [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Deferred Revenue | 175,326 | $ 175,646 |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Cumulative Revenue | 1,087,620 | |
Deferred Revenue | 175,326 | |
Total Consideration | 1,262,946 | |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | License Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Cumulative Revenue | 341,844 | |
Deferred Revenue | 0 | |
Total Consideration | 341,844 | |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | Co-development, information sharing & committee services [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Cumulative Revenue | 617,670 | |
Deferred Revenue | 0 | |
Total Consideration | 617,670 | |
AstraZeneca Agreements [Member] | U.S./RoW and China [Member] | China performance obligation [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Cumulative Revenue | 128,106 | |
Deferred Revenue | 175,326 | |
Total Consideration | $ 303,432 |
Collaboration Agreements, Lic_7
Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail) | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Europe [Member] | Astellas Agreement [Member] | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |
Transaction price, variable consideration from estimated future co-development billing | $ 5,800,000 |
Changes in revenue from changes to estimated variable consideration | 0 |
U.S./RoW and China [Member] | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |
Transaction price, variable consideration from estimated future co-development billing | 9,800,000 |
Changes in revenue from changes to estimated variable consideration | $ 0 |
Collaboration Agreements, Lic_8
Collaboration Agreements, License Agreement and Revenues - Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations Deferred Revenue (Parenthetical) (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Deferred revenue, net of current | $ 163,089 | $ 185,722 |
AstraZeneca Agreements [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Deferred Revenue | 175,326 | $ 175,646 |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Deferred revenue, net of current | 156,200 | |
Deferred Revenue | 175,300 | |
Net unbilled co-development revenue | $ 19,100 |
Collaboration Agreements, Lic_9
Collaboration Agreements, License Agreement and Revenues - Summary of Product Revenue, Net (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Disaggregation Of Revenue [Line Items] | ||
Total revenue | $ 36,161 | $ 60,827 |
Product Revenue, Net [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | 24,161 | 18,881 |
Product Revenue, Net [Member] | Direct Sales [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Gross revenue | 3,060 | 2,830 |
Total revenue | 2,789 | 2,658 |
Product Revenue, Net [Member] | Direct Sales [Member] | Discounts and Rebates [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | (273) | (175) |
Product Revenue, Net [Member] | Direct Sales [Member] | Sales Returns [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | 2 | 3 |
Product Revenue, Net [Member] | Sales To Falikang [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | 21,372 | 16,223 |
Gross transfer price | 34,249 | 22,726 |
Product Revenue, Net [Member] | Sales To Falikang [Member] | Profit Share [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | (14,988) | (8,849) |
Product Revenue, Net [Member] | Sales To Falikang [Member] | Net Transfer Price [Member] | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | 19,261 | 13,877 |
Product Revenue, Net [Member] | Sales To Falikang [Member] | Decrease in deferred revenue | ||
Disaggregation Of Revenue [Line Items] | ||
Total revenue | $ 2,111 | $ 2,346 |
Collaboration Agreements, Li_10
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Total revenue | $ 36,161 | $ 60,827 | |
Constrained for Future Recognition [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Total revenue | 2,100 | 2,300 | |
Product Revenue, Net [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Total revenue | 24,161 | 18,881 | |
China [Member] | Product Revenue, Net [Member] | |||
Contract with Customer, Liability [Abstract] | |||
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration | 300 | ||
AstraZeneca Agreements [Member] | |||
Contract with Customer, Liability [Abstract] | |||
Deferred Revenue | 175,326 | $ 175,646 | |
AstraZeneca Agreements [Member] | China [Member] | |||
Contract with Customer, Liability [Abstract] | |||
Deferred Revenue | 22,500 | ||
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member] | |||
Contract with Customer, Liability [Abstract] | |||
Reductions to gross accounts receivable | $ 2,200 | $ 500 |
Collaboration Agreements, Li_11
Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail) $ in Thousands | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
AstraZeneca Agreements [Member] | |
Contract with Customer Liability [Line Items] | |
Balance at December 31, 2022 | $ (175,646) |
Additions | (20,889) |
Currency Translation and Other | 163 |
Recognized as Revenue | 21,372 |
Balance at March 31, 2022 | (175,326) |
Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member] | |
Contract with Customer Liability [Line Items] | |
Balance at December 31, 2022 | (40,303) |
Additions | 0 |
Reclassified to Accrued Liability | 16,552 |
Recognized as Revenue | 377 |
Balance at March 31, 2022 | $ (23,374) |
Collaboration Agreements, Li_12
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | $ 36,161 | $ 60,827 |
Drug Product Revenue [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | 2,109 | 7,594 |
Drug Product Revenue [Member] | Japan [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | 1,700 | 9,800 |
Drug Product Revenue [Member] | Astellas Agreement [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | 2,100 | |
Drug Product Revenue [Member] | Astellas Agreement [Member] | Japan [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | 1,732 | 7,594 |
Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member] | ||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||
Drug product revenue recognized | $ 377 | $ 0 |
Collaboration Agreements, Li_13
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Deferred Revenue | $ 16,495 | $ 12,739 | |
Drug product revenue recognized | 36,161 | $ 60,827 | |
Other long-term liabilities | 7,063 | 6,440 | |
Astra Zeneca Agreements [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Royalty revenue recognized as drug product revenue | 21,372 | ||
Drug Product Revenue [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 2,109 | 7,594 | |
Drug Product Revenue [Member] | Astellas Agreement [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 2,100 | ||
Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 377 | 0 | |
Drug Product Revenue [Member] | Europe [Member] | Astellas Europe Agreement [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 16,600 | ||
Accrued liabilities | 57,400 | ||
Drug Product Revenue [Member] | Europe [Member] | Astellas Europe Agreement [Member] | Royalty Revenue [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Royalty revenue recognized as drug product revenue | 400 | ||
Drug Product Revenue [Member] | Japan [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 1,700 | 9,800 | |
Drug Product Revenue [Member] | Japan [Member] | Astellas Agreement [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 1,732 | 7,594 | |
Accrued liabilities | 3,200 | 6,500 | |
Other long-term liabilities | 1,600 | ||
Drug Product Revenue [Member] | API Shipment [Member] | Japan [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | $ 2,200 | ||
Bulk Drug Product [Member] | Astra Zeneca Agreements [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Drug product revenue recognized | 11,200 | ||
Accrued liabilities | 11,200 | $ 11,200 | |
Bulk Drug Product [Member] | Europe [Member] | Astellas Europe Agreement [Member] | |||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||
Accrued liabilities | 16,400 | ||
Accounts payable | $ 57,500 |
Collaboration Agreements, Li_14
Collaboration Agreements, License Agreement and Revenues - Eluminex Agreement - Additional Information 2 (Detail) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | |
Jul. 31, 2021 | Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |||
Total revenue | $ 36,161 | $ 60,827 | |
Eluminex [Member] | |||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |||
Aggregate consideration received for milestone and upfront payments | $ 8,000 | ||
Future manufacturing clinical regulatory and commercial milestone payments | 64,000 | ||
Commercial milestone | $ 36,000 | ||
Eluminex [Member] | Cornea Products [Member] | |||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |||
Percentage of product manufacturing costs until manufacturing technology fully transferred | 10% | ||
China [Member] | Eluminex [Member] | Biosynthetic Cornea [Member] | |||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | |||
Milestone Payments | 3,000 | ||
Manufacturing related milestone payments | $ 3,000 |
Collaboration Agreements, Li_15
Collaboration Agreements, License Agreement and Revenues - Summary of Amounts Recognized as Revenue (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | $ 36,161 | $ 60,827 |
License Revenue [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 6,000 | 22,590 |
License Revenue [Member] | Eluminex [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 6,000 | |
Other Revenue - Contract Manufacturing [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | 3,891 | 11,762 |
Other Revenue - Contract Manufacturing [Member] | Eluminex [Member] | ||
Revenue Recognition, Multiple-deliverable Arrangements [Line Items] | ||
Total revenue | $ 235 | $ 762 |
Equity method investment - Va_3
Equity method investment - Variable Interest Entity - Additional Information (Detail) | Mar. 31, 2023 |
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | Beijing Falikang Pharmaceutical Co Ltd | FibroGen Beijing [Member] | AstraZenecaAB [Member] | |
Acquisition And Variable Interest Entity [Line Items] | |
Percentage of outstanding shares acquired | 51.10% |
Equity method investment - Va_4
Equity method investment - Variable Interest Entity - Summary of Equity Method Investment (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Acquisition And Variable Interest Entity [Line Items] | ||
Beginning balance | $ 5,061 | |
Share of Net Income | 796 | $ 320 |
Ending balance | $ 5,884 | |
Beijing Falikang Pharmaceutical Co. Ltd [Member] | ||
Acquisition And Variable Interest Entity [Line Items] | ||
Ownership Percentage | 51.10% | |
Beginning balance | $ 5,061 | |
Share of Net Income | 796 | |
Currency Translation | 27 | |
Ending balance | $ 5,884 |
Fair Value Measurements - Fair
Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | $ 167,399 | $ 270,656 |
Corporate bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 41,304 | 82,008 |
Commercial paper [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 42,970 | 57,381 |
Asset-backed securities [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 2,484 | 2,474 |
Foreign government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 4,980 | |
Convertible promissory note [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 1,000 | |
Fair Value, Measurements, Recurring [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total fair value of financial assets | 210,139 | 290,537 |
Fair Value, Measurements, Recurring [Member] | Money market funds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Assets fair value disclosure | 42,740 | 19,881 |
Fair Value, Measurements, Recurring [Member] | Corporate bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 41,304 | 82,008 |
Fair Value, Measurements, Recurring [Member] | Commercial paper [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 42,970 | 57,381 |
Fair Value, Measurements, Recurring [Member] | U.S. government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 71,566 | 111,345 |
Fair Value, Measurements, Recurring [Member] | Agency bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 9,075 | 11,468 |
Fair Value, Measurements, Recurring [Member] | Asset-backed securities [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 2,484 | 2,474 |
Fair Value, Measurements, Recurring [Member] | Foreign government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 4,980 | |
Fair Value, Measurements, Recurring [Member] | Convertible promissory note [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 1,000 | |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total fair value of financial assets | 99,881 | 118,853 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Money market funds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Assets fair value disclosure | 42,740 | 19,881 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Corporate bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Commercial paper [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | U.S. government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 57,141 | 98,972 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Agency bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Asset-backed securities [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 1 [Member] | Foreign government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total fair value of financial assets | 110,258 | 170,684 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Money market funds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Assets fair value disclosure | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 41,304 | 82,008 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Commercial paper [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 42,970 | 57,381 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | U.S. government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 14,425 | 12,373 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Agency bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 9,075 | 11,468 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Asset-backed securities [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 2,484 | 2,474 |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Foreign government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 4,980 | |
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Convertible promissory note [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 1,000 | |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Total fair value of financial assets | 0 | 1,000 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Money market funds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Assets fair value disclosure | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Corporate bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Commercial paper [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | U.S. government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Agency bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Asset-backed securities [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | $ 0 | 0 |
Fair Value, Measurements, Recurring [Member] | Level 3 [Member] | Foreign government bonds [Member] | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Investments | $ 0 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Detail) $ in Millions | Mar. 31, 2023 USD ($) |
Fair Value Disclosures [Abstract] | |
Fair value of US treasury notes and bills transfered from level 1 to level 2 | $ 7 |
Balance Sheet Components - Sche
Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Cash and Cash Equivalents [Abstract] | ||
Cash | $ 145,810 | $ 135,819 |
Money market funds | 42,740 | 19,881 |
Total cash and cash equivalents | $ 188,550 | $ 155,700 |
Balance Sheet Components - Addi
Balance Sheet Components - Additional Information (Detail) - USD ($) | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Schedule of Available-for-sale Securities [Line Items] | |||
Cash and cash equivalents | $ 188,550,000 | $ 155,700,000 | |
Other-than-temporary impairment loss | 0 | $ 0 | |
API and bulk drug product price true-up | 30,758,000 | 75,055,000 | |
Foreign subsidiaries [Member] | |||
Schedule of Available-for-sale Securities [Line Items] | |||
Cash and cash equivalents | $ 98,900,000 | $ 92,500,000 |
Balance Sheet Components - Summ
Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | $ 168,534 | $ 273,189 |
Gross Unrealized Holding Gains | 2 | 5 |
Gross Unrealized Holding Losses | (1,137) | (2,538) |
Estimated Fair Value | 167,399 | 270,656 |
Corporate bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 41,760 | 83,080 |
Gross Unrealized Holding Gains | 1 | 0 |
Gross Unrealized Holding Losses | (457) | (1,072) |
Estimated Fair Value | 41,304 | 82,008 |
Commercial paper [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 42,970 | 57,381 |
Gross Unrealized Holding Gains | 0 | 0 |
Gross Unrealized Holding Losses | 0 | 0 |
Estimated Fair Value | 42,970 | 57,381 |
U.S. government bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 72,130 | 112,547 |
Gross Unrealized Holding Gains | 1 | 5 |
Gross Unrealized Holding Losses | (565) | (1,207) |
Estimated Fair Value | 71,566 | 111,345 |
Agency bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 9,183 | 11,690 |
Gross Unrealized Holding Gains | 0 | 0 |
Gross Unrealized Holding Losses | (108) | (222) |
Estimated Fair Value | 9,075 | 11,468 |
Foreign government bonds [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 5,007 | |
Gross Unrealized Holding Gains | 0 | |
Gross Unrealized Holding Losses | (27) | |
Estimated Fair Value | 4,980 | |
Convertible promissory note [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 1,000 | |
Gross Unrealized Holding Gains | 0 | |
Gross Unrealized Holding Losses | 0 | |
Estimated Fair Value | 1,000 | |
Asset-backed securities [Member] | ||
Schedule of Available-for-sale Securities [Line Items] | ||
Amortized Cost | 2,491 | 2,484 |
Gross Unrealized Holding Gains | 0 | 0 |
Gross Unrealized Holding Losses | (7) | (10) |
Estimated Fair Value | $ 2,484 | $ 2,474 |
Balance Sheet Components - Su_2
Balance Sheet Components - Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | $ 9,907 | $ 31,538 |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | (15) | (170) |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 88,953 | 159,627 |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | (1,122) | (2,368) |
Available for sale securities in continual unrealized loss position, estimated fair value | 98,860 | 191,165 |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | (1,137) | (2,538) |
Corporate bonds [Member] | ||
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | 2,469 | 6,738 |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | (7) | (147) |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 36,084 | 75,270 |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | (450) | (925) |
Available for sale securities in continual unrealized loss position, estimated fair value | 38,553 | 82,008 |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | (457) | (1,072) |
U.S. government bonds [Member] | ||
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | 4,955 | 22,326 |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | (1) | (13) |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 43,794 | 67,909 |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | (564) | (1,194) |
Available for sale securities in continual unrealized loss position, estimated fair value | 48,749 | 90,235 |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | (565) | (1,207) |
Agency bonds [Member] | ||
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | 0 | 0 |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | 0 | 0 |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 9,075 | 11,468 |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | (108) | (222) |
Available for sale securities in continual unrealized loss position, estimated fair value | 9,075 | 11,468 |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | (108) | (222) |
Asset-backed securities [Member] | ||
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | 2,483 | 2,474 |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | (7) | (10) |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 0 | 0 |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | 0 | 0 |
Available for sale securities in continual unrealized loss position, estimated fair value | 2,483 | 2,474 |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | $ (7) | (10) |
Foreign government bonds [Member] | ||
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items] | ||
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value | 0 | |
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses | 0 | |
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value | 4,980 | |
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses | (27) | |
Available for sale securities in continual unrealized loss position, estimated fair value | 4,980 | |
Available for sale securities in continual unrealized loss position, gross unrealized holding losses | $ (27) |
Balance Sheet Components - Sc_2
Balance Sheet Components - Schedule of Inventory (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Schedule of Investments [Abstract] | ||
Raw materials | $ 1,226 | $ 1,241 |
Work-in-progress | 37,273 | 36,003 |
Finished goods | 3,957 | 3,192 |
Total inventories | $ 42,456 | $ 40,436 |
Balance Sheet Components - Sc_3
Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Accrued Liabilities, Current [Abstract] | ||
Preclinical and clinical trial accruals | $ 42,953 | $ 57,780 |
API and bulk drug product price true-up | 30,758 | 75,055 |
Payroll and related accruals | 12,230 | 22,562 |
Accrued co-promotion expenses - current | 36,688 | 36,677 |
Roxadustat profit share to AstraZeneca | 7,311 | 7,280 |
Property taxes and other taxes | 8,041 | 7,691 |
Professional services | 8,354 | 5,480 |
Current portion of liability related to sale of future revenues | 3,212 | 0 |
Other | 7,495 | 7,248 |
Total accrued and other current liabilities | $ 157,042 | $ 219,773 |
Liability Related to Sale of _3
Liability Related to Sale of Future Revenues - Additional Information (Details) - USD ($) | 3 Months Ended | ||
Nov. 04, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | $ 36,161,000 | $ 60,827,000 | |
NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Effective annual interest rate related to sale of future revenues | 19.64% | ||
NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] | Minimum [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Prepayment amount of 2024 to 2030 | $ 80,000,000 | ||
NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] | Maximum [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Prepayment amount of 2024 to 2030 | 125,000,000 | ||
NovaQuest Capital Management [Member] | Payment Period One [Member] | Revenue Interest Financing Agreement [Member] | Minimum [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Revenue interest payment | 62,500,000 | ||
NovaQuest Capital Management [Member] | Payment Cap Date on or before December 31, 2028 [Member] | Revenue Interest Financing Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Maximum payment cap amount | 100,000,000 | ||
NovaQuest Capital Management [Member] | Payment Cap Date on or after January 1, 2029 [Member] | Revenue Interest Financing Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Maximum payment cap amount | 112,500,000 | ||
NovaQuest Capital Management [Member] | Payment Cap Date after January 1, 2030 [Member] | Revenue Interest Financing Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Maximum payment cap amount | 125,000,000 | ||
NovaQuest Capital Management [Member] | Payment Period Two [Member] | Revenue Interest Financing Agreement [Member] | Minimum [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Revenue interest payment | 125,000,000 | ||
Product [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | $ 24,161,000 | 18,881,000 | |
Product [Member] | NovaQuest Capital Management [Member] | Revenue Interest Financing Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Revenue interest payment | 10,000,000 | ||
License [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | 6,000,000 | 22,590,000 | |
Other Revenue - Contract Manufacturing [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | 3,891,000 | 11,762,000 | |
Astellas Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Future revenue granted | $ 50,000,000 | ||
Percentage of revenue interest on global net sales | 100% | ||
Astellas Agreement [Member] | Maximum [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Revenue payment cap amount | 125,000,000 | ||
Astellas Agreement [Member] | Product [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Percentage of revenue sold | 22.50% | ||
Astellas Agreement [Member] | Milestone payments [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Percentage of revenue sold | 10% | ||
Astellas Agreement [Member] | Milestone payments [Member] | Payment Period One [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Percentage of revenue sold | 20% | ||
Development Revenue [Member] | Astellas Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | 1,600,000 | ||
Drug Product Revenue [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | 2,109,000 | $ 7,594,000 | |
Drug Product Revenue [Member] | Astellas Agreement [Member] | |||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
Total revenue | 2,100,000 | ||
Non-cash interest expense related to drug product revenue | $ 2,200,000 |
Liability Related to Sale of _4
Liability Related to Sale of Future Revenues - Schedule of Activity of Liability Related to Sale of Future Revenues (Detail) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Liability Related to Sale of Future Royalties [Abstract] | ||
Liability related to sale of future revenues - beginning balance | $ 49,333 | |
Interest expense recognized | 2,249 | $ 0 |
Liability related to sale of future revenues - ending balance | 51,582 | |
Less: Current portion classified to accrued and other current liabilities | (3,212) | |
Liability related to sale of future revenues, non-current | $ 48,370 |
At-the-Market Program - Additio
At-the-Market Program - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | ||
Feb. 27, 2023 | Mar. 31, 2023 | Mar. 31, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Issuance of common stock under ATM Program | $ 31,131 | ||
Proceeds from sale of common stock | $ 907 | $ 183 | |
ATM Program [Member] | |||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||
Issuance of common stock under ATM Program | $ 200,000 | ||
Issuance of common stock under ATM Program shares | 1,541,579 | ||
Proceeds from sale of common stock | $ 31,100 | ||
Net of commissions to sales agents | $ 30,800 | ||
Weighted-average offering prices per share | $ 20.25 |
Related Party Transactions - Ad
Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Related Party Transaction [Line Items] | |||
Accounts receivable from related parties | $ 11,563 | $ 12,088 | |
Accrued liabilities to related party | 19,594 | 63,886 | |
Investment income (loss) | 796 | $ 320 | |
Equity method investments | 5,884 | 5,061 | |
Astellas [Member] | |||
Related Party Transaction [Line Items] | |||
Drug product revenue from a related party | 2,100 | 7,600 | |
Due to related parties | 78,700 | 63,900 | |
Astellas [Member] | Collaborative Arrangement [Member] | |||
Related Party Transaction [Line Items] | |||
Accounts receivable from related parties | 1,600 | 1,500 | |
Deferred Revenue | 23,400 | 40,300 | |
Astellas [Member] | License and Development [Member] | Collaborative Arrangement [Member] | |||
Related Party Transaction [Line Items] | |||
Revenue related to collaboration agreements | 1,600 | 27,800 | |
Falikang [Member] | |||
Related Party Transaction [Line Items] | |||
Accounts receivable from related parties | 9,900 | 10,500 | |
Investment income (loss) | 800 | 300 | |
Equity method investments | $ 5,900 | $ 5,100 | |
Percentage of outstanding shares owned | 51.10% | ||
Falikang [Member] | Collaborative Arrangement [Member] | |||
Related Party Transaction [Line Items] | |||
Revenue related to collaboration agreements | $ 21,400 | $ 16,200 |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Detail) $ in Millions | 2 Months Ended | 3 Months Ended |
May 31, 2021 PutativeClassAction | Mar. 31, 2023 USD ($) | |
Commitments And Contingencies [Line Items] | ||
Operating lease liability | $ 86.8 | |
Outstanding non-cancelable purchase obligations | 51.9 | |
Putative securities class action complaints filed | PutativeClassAction | 5 | |
Manufacture and Supply of Roxadustat [Member] | ||
Commitments And Contingencies [Line Items] | ||
Outstanding non-cancelable purchase obligations | 4.1 | |
Manufacture and Supply of Pamrevlumab [Member] | ||
Commitments And Contingencies [Line Items] | ||
Outstanding non-cancelable purchase obligations | 22.4 | |
Other Purchases [Member] | ||
Commitments And Contingencies [Line Items] | ||
Outstanding non-cancelable purchase obligations | 25.4 | |
Research and Preclinical Stage Development Programs [Member] | ||
Commitments And Contingencies [Line Items] | ||
Maximum future milestone payments | $ 697.9 |
Subsequent Event - Additional I
Subsequent Event - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | ||
May 05, 2023 | Apr. 29, 2023 | Mar. 31, 2023 | |
Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Repayment description | The Term Loans shall mature on May 8, 2026. The Term Loans will not be subject to amortization payments. The Company is permitted to prepay the Term Loans from time to time, in whole or in part, subject to payment of a make-whole amount equal to the unpaid principal amount of the portion of the Term Loans being repaid or prepaid, plus accrued and unpaid interest of the portion of the Term Loans being repaid or prepaid, plus an amount equal to the remaining scheduled interest payments due on such portion of the Term Loans being repaid or prepaid as if such Term Loans were to remain outstanding until the scheduled maturity date.During the term of the Term Loans, the Company is required to maintain a minimum balance of $30.0 million of unrestricted cash and cash equivalents held in accounts in the United States, tested monthly on each interest payment date (after netting the monthly interest payment then due). | ||
Subsequent Event [Member] | Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Interest rate per annum | 14% | ||
Fortis Therapeutics [Member] | Subsequent Event [Member] | |||
Subsequent Event [Line Items] | |||
Product development obligations | $ 5 | ||
Payment to options exercised | 80 | ||
Contingent payment associated with business acquisition | $ 200 | ||
Initial Term Loan [Member] | Subsequent Event [Member] | Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Term loan | $ 75 | ||
Delayed Draw Term Loan [Member] | Subsequent Event [Member] | Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Term loan | $ 37.5 | ||
Maximum term loan funding period from signing date | 24 days | ||
Delayed Draw Term Loan 2 | Subsequent Event [Member] | Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Term loan | $ 37.5 | ||
Minimum [Member] | Subsequent Event [Member] | Debt Financing Agreement [Member] | |||
Subsequent Event [Line Items] | |||
Unrestricted cash and cash equivalent balance required to maintain in accounts | $ 30 |